Section 3 of 6
Product information and disease description
379 evidence topics · 173 sources
Product description
Phase of product development
Regulatory status: Submission planned; NDA filing anticipated in the first half of 2027
Launch
No evidence found.
Commercial readiness and launch preparation: no launch date stated
Investigational status and current development phase
Phase 3 topline results: Voyage reported August 2026 and Panorama reported September 2026
Phase 3 initiation: first participant dosed in Voyage in December 2024
Breakthrough Therapy designation for generalized anxiety disorder: March 2024
Breakthrough Therapy designation for major depressive disorder: September 2026
End-of-phase 2 meeting with the FDA: completed June 2024
Investigational new drug application for the phase 2b trial: cleared January 2022
Innovation Passport under the UK Innovative Licensing and Access Pathway: December 2024
Development outside the United States: regulatory strategy
Controlled substance scheduling: rescheduling by the DEA and states required after approval
Executive Order 14401 of April 2026: priority vouchers and timely rescheduling of psychedelic drugs
Patent protection for the orally disintegrating tablet
NDA submission timing: no date stated, April 2026, superseded in September 2026
Voyage topline timing: first half of 2026, stated March 2025 to November 2025, superseded in January 2026
Voyage topline timing: second quarter of 2026, stated January 2026, superseded in February 2026
Voyage topline timing: early third quarter of 2026, stated February 2026 to May 2026, superseded in August 2026
Panorama topline timing: second half of 2026, stated March 2025 to February 2026, superseded in April 2026
Panorama topline timing: late third quarter of 2026, stated April 2026 and May 2026, superseded in August 2026
Phase 3 initiation planned for the second half of 2024, stated March 2024 and June 2024, superseded in December 2024
FDA clinical hold on the phase 2b IND, December 2021, superseded in January 2022
Product information
Generic, brand name and therapeutic class of product
Manufacturer: Definium Therapeutics
Corporate name change from Mind Medicine (MindMed) Inc. to Definium Therapeutics, January 2026
Nasdaq ticker effective date of January 13, 2026, stated January 12, 2026, superseded on January 13, 2026
Product names: development codes DT120, MM120, and MM-120
Nonproprietary names: United States adopted name lysergide tartrate and international nonproprietary name lysergide
Therapeutic class: ergoline derivative and classic serotonergic psychedelic, partial agonist at 5-HT2A receptors
Ownership history: exclusive collaboration with the University Hospital Basel Liechti Lab from April 2020
Ownership history: exclusive license to Catalent Zydis orally disintegrating tablet technology, August 2023
Dosage forms and strengths
Phase 3 dosage form: orally disintegrating tablet using Zydis technology
Strengths studied in phase 3: 100 µg, and 50 µg as a control arm in Panorama
Strengths studied in phase 2b: 25, 50, 100, and 200 µg freebase equivalent
Phase 1 bridging study: four 25-µg capsules compared with one 100-µg orally disintegrating tablet
Commercial dosage form, strengths, and package configuration
No evidence found.
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
Controlled Substances Act classification: Schedule I hallucinogenic substance, DEA controlled substance code 7315
| Field | Quoted record |
|---|---|
| Schedule I category | “Hallucinogenic substances” |
| Substance | “Lysergic acid diethylamide” |
| Administration Controlled Substances Code Number | “7315” |
AHFS Pharmacologic-Therapeutic Classification and Anatomical Therapeutic Chemical code
No evidence found.
Indication
Indication under development: adults with generalized anxiety disorder
Labeling scope sought and filing strategy across generalized anxiety disorder and major depressive disorder
Other indications in development: major depressive disorder and posttraumatic stress disorder
Proposed labeled indication submitted to a regulator
No evidence found.
Pharmacology
Mechanism of action
Classic serotonergic psychedelic and partial agonist at serotonin-2A receptors
Registry description of the investigational product
Mechanism in anxiety not established
“Lysergide, or lysergic acid diethylamide (LSD), is a semisynthetic psychedelic drug in the ergoline family.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although LSD’s precise mechanism of action in the treatment of psychiatric illness is unknown, mechanistic hypotheses implicate its acute psychological effects (mediated by agonism of the 5-HT2A receptor) and its sustained increases in neuroplasticity in a variety of brain regions as potentially responsible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dependence of the acute response on serotonin-2A receptors: ketanserin studies
“Administration of the 5-HT 2A antagonist ketanserin before LSD almost fully blocks the acute subjective response to LSD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings are consistent with an interaction between ketanserin and LSD and the view that LSD produces its psychedelic effects only when occupying 5-HT 2A receptors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ketanserin effectively prevented the response to 200 µg LSD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The full psychedelic effects of LSD are primarily mediated by serotonin 5-HT 2A receptor activation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serotonin receptor activity of LSD and its metabolites in vitro
“LSD and nor-LSD were pharmacologically active at the 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT2C receptors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nor-LSD mainly differed from the parent compound by having a lower affinity to the 5-HT2C receptor.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“O-H-LSD displayed substantially weaker affinity and activity at serotonergic receptors in comparison to LSD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics
Thorough QT study of DT120 ODT: design and QT result
“Phase 1 TQT (n = 59)” (opens the source at this quote in a new tab)
“Randomized, double-blind in healthy volunteers” (opens the source at this quote in a new tab)
“Single DT120: 100-μg ODT or 300-μg ODT” (opens the source at this quote in a new tab)
“DT120 was not shown to prolong the QT interval” (opens the source at this quote in a new tab)
Thorough QT study of DT120 ODT: treatment-emergent adverse events
| Measure | Phase 1 TQT study, DT120 ODT (n = 58) |
|---|---|
| Any TEAE | “57 (98.3)” |
| TEAE leading to treatment withdrawal | “0” |
| Mild | “27 (46.6)” |
| Moderate | “27 (46.6)” |
| Severe | “3 (5.2)” |
| Any related TEAE | “57 (98.3)” |
QTc interval after LSD with and without paroxetine in healthy participants
“LSD did not increase the QTc interval at its peak effect at 3.5 h after administration compared with 1 h before in either the paroxetine or placebo condition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no cases of QTc time increases >450 ms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vital signs across DT120 phase 1 and phase 2b studies
Heart rate, blood pressure, and body temperature by dose in healthy participants
“The physiologic effects of LSD were moderate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“None of the subjects had systolic blood pressure > 180 mmHg at any time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Peak heart rate > 100 beats/min was observed in 0%, 6%, 20%, and 25% of the subjects at 25, 50, 100, and 200 µg, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Peak body temperature > 38° was observed in 0%, 11%, 7%, and 34% at 25, 50, 100, and 200 µg, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Kidney and liver function parameters were unaltered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose-response of subjective effects and ceiling at 100 µg in healthy participants
“LSD showed dose-proportional pharmacokinetics and first-order elimination and dose-dependently induced subjective responses starting at the 25 µg dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A ceiling effect was observed for good drug effects at 100 µg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 200 µg dose of LSD induced greater ego dissolution than the 100 µg dose and induced significant anxiety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average duration of subjective effects increased from 6.7 to 11 h with increasing doses of 25–200 µg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Maximal ratings of > 50% good drug effects were reached in 37%, 91%, 96%, and 91% of the LSD administrations at 25, 50, 100, and 200 µg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Maximal ratings of > 50% bad drug effects were reached in 0%, 9%, 27%, 31% at 25, 50, 100, and 200 µg, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concentration-effect relationship
“A close relationship was observed between the LSD concentration and subjective response within subjects, with moderate counterclockwise hysteresis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Half-maximal effective concentration values were in the range of 1 ng/mL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The effects of LSD were related to changes in plasma concentrations over time, with no evidence of acute tolerance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Onset and peak of subjective effects: ODT versus capsule
Time course of a dosing session described by the sponsor
Duration of subjective effects by dose in healthy participants
“The subjective effects lasted (mean ± standard deviation) 8.2 ± 2.1 and 11.6 ± 1.7 h for the 100- and 200-µg LSD doses, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subjective peak effects were reached 2.8 and 2.5 h after administration of LSD 100 and 200 µg, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serotonin-2B receptor activity and valvulopathy: regulatory expectations
Pharmacokinetics
ODT versus capsule: relative bioavailability study design (MM-120-101)
ODT versus capsule: published abstract results
ODT versus capsule: company analysis of pharmacokinetic parameters, March 2024
Formulation rationale stated by the sponsor
Food effect study of DT120 ODT: design
“Phase 1 PK Food Effect (n = 64)” (opens the source at this quote in a new tab)
“Cohort 1: 100-μg ODT fasted vs high-fat meal” (opens the source at this quote in a new tab)
“Cohort 2: 100-μg ODT fasted vs low-fat meal” (opens the source at this quote in a new tab)
“Open-label, crossover in healthy volunteers” (opens the source at this quote in a new tab)
Food effect study of DT120 ODT: treatment-emergent adverse events by cohort
| Measure | DT120 ODT + high-fat meal (n = 31) | DT120 ODT + low-fat meal (n = 28) |
|---|---|---|
| Any TEAE | “31 (100.0)” | “28 (100.0)” |
| TEAE leading to treatment withdrawal | “1 (3.2)” | “2 (7.1)” |
| Mild | “24 (77.4)” | “22 (78.6)” |
| Moderate | “7 (22.6)” | “5 (17.9)” |
| Severe | “0” | “1 (3.6)” |
| Any related TEAE | “31 (100.0)” | “28 (100.0)” |
Food effect study of DT120 ODT: UK research ethics and registry records
“REC reference 24/WA/0003” (opens the source at this quote in a new tab)
“Date of REC Opinion 22 Mar 2024” (opens the source at this quote in a new tab)
“Phase I trial MM-120-102” (opens the source at this quote in a new tab)
“ref: 24/WA/0003” (opens the source at this quote in a new tab)
“Phase I study in 32 healthy volunteers” (opens the source at this quote in a new tab)
“Non randomised study” (opens the source at this quote in a new tab)
“Completion date 29/08/2024” (opens the source at this quote in a new tab)
Food effect: regulatory expectation for oral psychedelic drugs
Absorption, peak concentration, and half-life of oral LSD
“Mean (95% confidence interval) maximal LSD concentrations were 1.8 ng/mL (1.6-2.0) and 3.4 ng/mL (3.0-3.8) after the administration of 85 and 170 μg LSD, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Maximal concentrations were achieved on average after 1.7 h.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Elimination half-lives were 3.7 h (3.4-4.1) and 4.0 h (3.6-4.4), for 85 and 170 μg LSD, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“LSD exhibited dose-proportional pharmacokinetics and first-order elimination kinetics and dose-dependent duration and intensity of subjective effects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Geometric mean (95% confidence interval) maximum plasma concentration values of 1.3 (1.2–1.9) and 3.1 (2.6–4.0) ng/mL were reached 1.4 and 1.5 h after administration of 100 and 200 µg LSD, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The plasma half-life was 2.6 h (2.2–3.4 h).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Oral LSD presented dose-proportional pharmacokinetics and first-order elimination up to 12 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Absolute oral bioavailability and bioequivalence of LSD base and tartrate
“We used a randomized, double‐blind, placebo‐controlled, five‐period crossover design in 20 healthy participants to investigate an ethanolic drinking solution of LSD base, a watery drinking solution of LSD tartrate, a rapid dissolvable tablet of LSD base, an intravenous formulation of LSD tartrate, and corresponding placebos.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All oral formulations were bioequivalent, with the ethanolic base solution as a reference.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The absolute bioavailability of oral LSD was 80% and similar for all tested formulations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In conclusion, dosing with LSD base and tartrate can be considered bioequivalent with high and similar oral bioavailability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Metabolism and urinary excretion
“Only 1% of the administered dose was recovered from urine unchanged within the first 24 h, 16% was eliminated as 2-oxo-3-hydroxy-LSD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“LSD is extensively metabolized and shows dose-proportional urinary recovery.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cytochrome P450 enzymes in LSD metabolism
“CYP2D6, 2E1, and 3A4 significantly contributed to the formation of nor-LSD, and CYP1A2, 2C9, 2E1, and 3A4 were significantly involved in the formation of O-H-LSD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“To conclude, human liver microsomes converted only small amounts of LSD to nor-LSD and O-H-LSD but several CYPs significantly contributed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Not applicable.
Special populations
CYP2D6 poor metabolizers
“Individuals with no functional CYP2D6 (i.e., poor metabolizers) had longer LSD half-lives and approximately 75% higher parent drug and main metabolite 2-oxo-3-hydroxy LSD area-under-the-curve blood plasma concentrations compared with carriers of functional CYP2D6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Non-functional CYP2D6 metabolizers also exhibited greater alterations of mind and longer subjective effect durations in response to LSD compared with functional CYP2D6 metabolizers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CYP2D6 is associated with several phenotypes, ranging from poor metabolizers (PMs; 5–10% in Caucasians) to ultra-rapid metabolizers (UMs; 3–5% in Caucasians), with different underlying genotypes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Geno- or phenotyping may be useful in patients who undergo LSD-assisted therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the present findings, CYP2D6 PMs may benefit from approximately 50% lower doses than those that are used in functional CYP2D6 individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age range studied in the generalized anxiety disorder trials
Personal or family history of psychotic or bipolar disorder and other excluded conditions
Pregnancy and contraception in the trials
Preexisting valvulopathy or pulmonary hypertension in multiple-dose studies
Drug/Drug, drug/disease interactions
Effects of other drugs on Lysergide
Paroxetine (selective serotonin reuptake inhibitor and strong CYP2D6 inhibitor)
“The present study investigated the acute response to single doses of LSD (100 μg) after daily administration of paroxetine (10 mg for 7 days, followed by 20 mg for 35 days) or placebo (42 days) using a randomized, double‐blind, cross‐over design in 23 healthy participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Paroxetine did not alter pleasant subjective effects of LSD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The strong cytochrome P450 2D6 (CYP2D6) inhibitor paroxetine led to higher maximal concentrations and total exposures of LSD (geometric mean ratios of 1.4 and 1.5, respectively) indicating relevant involvement of CYP2D6 in its metabolism.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The extent of this inhibition was nominally highest in genetic CYP2D6 normal metabolizers and lowest in poor metabolizers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The pharmacokinetic and pharmacodynamic interactions indicate that no dose adjustment of LSD seems necessary in the presence of an SSRI that inhibits CYP2D6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For SSRIs that do not relevantly inhibit CYP2D6, a dose increase of LSD might be appropriate, but due to lacking data and potential other pharmacokinetic interactions with these compounds, no definitive dose recommendation can be made.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other CYP2D6 inhibitors
“A similar or substantial increase in plasma LSD concentrations could be expected when patients who are on antidepressants that inhibit CYP2D6 (e.g., fluoxetine, paroxetine, duloxetine, and bupropion) and are treated with LSD-assisted therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This interaction warrants further study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consideration should also be given to discontinuing CYP2D6 inhibitors and allowing sufficient time for the enzyme to regenerate (up to 2 weeks) before LSD is used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Alternatively, in the presence of CYP2D6 inhibitors, the dose of LSD should be reduced, based on the present findings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MDMA co-administration
“MDMA slightly altered the pharmacokinetics of LSD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The plasma LSD elimination half-life was longer in the LSD + MDMA condition (5.2 h) compared with LSD alone (3.9 h; T = 5.00; p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, MDMA and LSD primarily interact pharmacokinetically and not pharmacodynamically.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MDMA is a strong inhibitor of CYP2D6, turning any CYP2D6 extensive or rapid metabolizer into a poor metabolizer within approximately 2 h” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ketanserin given after LSD
“Ketanserin reversed the acute response to LSD, thereby significantly reducing the duration of subjective effects from 8.5 hours with placebo to 3.5 hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ketanserin did not alter the pharmacokinetics of LSD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ketanserin can effectively be used as a planned or rescue option to shorten and attenuate the LSD experience in humans in research and LSD-assisted therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ketanserin, olanzapine, and lorazepam as rescue medications: registered study
Enzyme induction and inhibition in vitro
“Enzyme induction with rifampicin distinctly increased the formation of both metabolites, whereas treatment with omeprazole only slightly increased formation of nor-LSD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Genetic polymorphisms and drug interactions could therefore influence pharmacokinetics and pharmacodynamics of LSD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Drug-drug interaction studies in humans are required to further assess the clinical relevance of these findings.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Antidepressants and lithium: regulatory guidance on pharmacodynamic interactions
Effects of Lysergide on other drugs
MDMA pharmacokinetics with and without LSD 100 µg
Dosing and administration
Dosage
Phase 3 dose: single 100 µg DT120 ODT
Symptom-triggered open-label redosing in the 40-week extension
Dose selection from the phase 2b dose-finding trial
“In this phase 2b, multicenter, double-blind, placebo-controlled trial, participants with GAD were randomized equally to receive a single (freebase equivalent) treatment dose with 25 µg, 50 µg, 100 µg, or 200 µg of MM120 or placebo without stratification (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 100-µg dose of MM120 was determined to be optimal, demonstrating a statistically significant change in GAD that exceeded the changes seen with lower MM120 doses or with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 200-µg dose of MM120 was associated with more frequent AEs without improvements in efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings support the selection of 100-µg dose of MM120 for pivotal trials to assess its efficacy, durability, and safety in the treatment of GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose-response in healthy participants above 100 µg
“Therefore, LSD doses higher than 100 µg produced no further increases in good drug effects but more ego dissolution and anxiety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These results may assist with dose finding for future LSD research.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Characterization of the 100 µg dose in an independent drug review
“The phase 2b dose-finding study provides a credible signal of rapid and durable anxiolytic activity after one 100 microgram administration without protocol-mandated psychotherapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, DT120 should not be described as microdosing or modified release: 100 micrograms is a perceptible psychedelic dose, whereas controlled microdosing studies have generally used 5-20 micrograms, and the pivotal product is described publicly as a fast-dissolving orally disintegrating tablet.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Administration
Orally disintegrating tablet
Required 8-hour monitoring and end-of-session checklist in the Phase 3 trials
End-of-session checklist content and development
Session length in Voyage: topline announcement
Session length in Voyage: congress poster
Session length in Panorama and across the Phase 3 trials
Dosing session monitors and on-call clinician in the Phase 3 trials
Phase 2b dosing session procedures and 12-hour monitoring
“On the dosing day, participants received a single oral dose of MM120 or placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Each participant was continuously monitored on-site for safety and comfort by the same 2 dosing session monitors who conducted the participant’s educational session during the baseline visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participant dosing sessions were conducted individually in a private aesthetically pleasant room.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were offered standardized music and eyeshades and they could lie down, move freely around the room, read, write, or draw.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Vital signs were measured throughout the dosing session and a physician was on-site in case comfort medications were needed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Starting 8 hours after the dose, participants were assessed hourly to characterize the resolution of the drug effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Continuous monitoring was required for a minimum of 12 hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 2b: time to meet criteria to end the session at 100 µg
“In the 100-µg dose group, 45.0% of participants met criteria to safely end the session at 8 hours, 70.0% at 9 hours, 87.5% at 10 hours, 90.0% at 11 hours, and 97.5% at 12 hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All participants remained at the study site until 12 hours after the dosing session regardless of meeting criteria to safely end the session per the trial protocol (Supplement 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Regulatory expectations for monitoring a psychedelic treatment session
Access and distribution
Current access through clinical trials only
Schedule I status: product rescheduling required before commercial distribution
DEA registration of clinical trial sites and importation for the trials
Manufacturing quotas for the active ingredient after approval
Planned delivery through certified third-party treatment sites and a possible REMS
Monitoring requirement in the pivotal trials and the end-of-session checklist as a basis for a potential REMS
Planned sites of care: interventional psychiatry clinics
Manufacturing and supply: contract manufacturers and a single supplier of lysergide tartrate
Distribution channel and specialty pharmacy arrangements
No evidence found.
Co-prescribed/Concomitant therapies
Phase 3: exclusion of medications that could not be discontinued
Phase 2b: taper and washout of mood and anxiety medications
“The exclusion criteria included contraindicated medical or psychiatric conditions and inability or unwillingness to discontinue therapeutics with potential drug-drug interaction or anxiolytic effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants taking mood or anxiety medications at screening were required to discontinue them under the supervision of site physicians.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Before the baseline visit, a medication washout period of 5 half-lives or greater was required.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 2b: medications tapered at enrollment
“At screening, 84% of participants required tapering prohibited medications, 16% were treatment-naive, and 18% were receiving psychotherapy at the time of enrollment; psychotherapy was allowed to continue through the trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the participants who required tapering prohibited medications, 43% were taking serotonin reuptake inhibitors, 34% were taking benzodiazepines, and 19% were taking antipsychotics or antiepileptics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants may have tapered multiple medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 2b: prohibited substances
“Disclosure or detection of the use of prohibited substances, including tetrahydrocannabinol, was cause for screening failure or discontinuation as was the use of any psychedelic within the past 2 years or more than 10 times within the past 10 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monotherapy design and unstudied concomitant use
Psychotherapy: phase 2b rules
“Participants undergoing psychotherapy at the time of screening could enroll but could not discontinue or modify session frequency during the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants not receiving psychotherapy at screening could not initiate it during the trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Engaging in psychotherapy with the participant was explicitly prohibited by the trial protocol (Supplement 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psychotherapy: sponsor treatment paradigm
Concomitant selective serotonin reuptake inhibitor: healthy-participant interaction study
“The present findings suggest that add‐on treatment with LSD to an SSRI is well‐tolerated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No signs of serotonergic toxicity occurred in either study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SSRIs did not increase the psychedelic‐induced cardiovascular stimulation or elevation of body temperature.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, SSRI therapy has been discontinued before psychedelic administration in clinical Phase II trials, with the exception of one open‐label trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, SSRI discontinuation carries the risk of symptom relapse and withdrawal symptoms, including depressed mood.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prohibited concomitant medications: regulatory guidance
Effect of Lysergide on quality measures
Anxiety Response at 6 Months (MBHR2) and Use of Anxiety Severity Measure (MBHR1): Merit-based Incentive Payment System registry measures
Use of High-Risk Medications in Older Adults: benzodiazepine rate and the severe generalized anxiety disorder exception
Lysergide-specific effect on quality measures
No evidence found.
Product comparison
Effect sizes of DT120 placed beside approved GAD treatments: company presentation
Effect sizes of approved GAD drug classes: meta-analysis of 21 placebo-controlled trials cited by the company
“We conducted an effect size (ES) analysis of 21 double-blind placebo-controlled trials of medications treating DSM-III-R, DSM-IV or ICD-10 GAD using HAM-A change in score from baseline or endpoint score as the main efficacy measure.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“comparing all drugs versus placebo, the ES was 0.39. Mean ESs, excluding children, were PGB: 0.50, AH: 0.45, SNRI: 0.42, BZ: 0.38, SSRI: 0.36, AZA: 0.17 and CAM: -0.31.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HAM-A differences from placebo for approved and off-label GAD drugs: network meta-analysis of 89 trials
“This analysis is based on 89 trials, which included 25 441 patients randomly assigned to 22 different active drugs or placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Duloxetine (MD -3·13, 95% credible interval [CrI] -4·13 to -2·13), pregabalin (MD -2·79, 95% CrI -3·69 to -1·91), venlafaxine (MD -2·69, 95% CrI -3·50 to -1·89), and escitalopram (MD -2·45, 95% CrI -3·27 to -1·63) were more efficacious than placebo with relatively good acceptability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Quetiapine (MD -3·60 95% CrI -4·83 to -2·39) had the largest effect on HAM-A but it was poorly tolerated (odds ratio 1·44, 95% CrI 1·16-1·80) when compared with placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
DT120 HAM-A differences from placebo in the phase 3 trials
FDA-approved pharmacotherapies for GAD in adults
“Escitalopram has been approved by the FDA for the treatment of GAD in adults” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As an FDA-approved treatment for GAD in adults, immediate release paroxetine has been studied extensively and multiple studies support its efficacy in adults with GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In adults with GAD, venlafaxine (75–225 mg/day) effectively reduces anxiety symptoms [36–38] and was the first FDA-approved antidepressant for the treatment of GAD in this age group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Duloxetine, a selective 5-HT and norepinephrine reuptake inhibitor, is FDA-approved for the treatment of GAD, MDD, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Buspirone, a non-benzodiazepine anxiolytic and 5-HT1A receptor agonist, is approved for the treatment of GAD in adults” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As such, alprazolam is the only benzodiazepine to be formally approved by the FDA for the treatment of GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Most recent FDA approval of a new drug for GAD: differing company statements
Dosing paradigm: single administered dose compared with daily oral therapy
Monitored-administration model: esketamine nasal spray under the SPRAVATO REMS
Monitored-administration model: DT120 session length in the phase 3 trials
Prescriber intent to administer DT120 compared with esketamine: company market research
| Response of high-priority GAD prescribers | DT120 ODT | Esketamine |
|---|---|---|
| Prescribe and administer the treatment in own practice | “51%” | “26%” |
| Refer out (for DT120, the treatment; for esketamine, for esketamine) | “40%” | “61%” |
| Only discuss if a patient raises it (DT120), or refer out for evaluation without specifying esketamine | “9%” | “14%” |
LSD compared with psilocybin: effect duration in healthy participants
| Effect | 15 mg psilocybin | 30 mg psilocybin | 100 µg LSD | 200 µg LSD |
|---|---|---|---|---|
| Effect duration (h), mean ± SD | “5.6 ± 2.2”View highlighted excerpt for this quote | “6.5 ± 2.4”View highlighted excerpt for this quote | “9.3 ± 3.2”View highlighted excerpt for this quote | “11 ± 3.7”View highlighted excerpt for this quote |
“The doses of 100 and 200 µg LSD and 30 mg psilocybin produced comparable subjective effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LSD at both doses had clearly longer effect durations than psilocybin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The elimination half-life values of LSD and psilocin were an average of ~4 h and 2.5 h, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other psychedelic and serotonergic agents in development for GAD and depressive disorders, as listed by the company
Head-to-head clinical comparison of DT120 with an approved GAD treatment
No evidence found.
Place of product in therapy
Disease description
Definition and etiology
Definition: persistent, excessive, and difficult-to-control worry about everyday concerns
Definition: core features of generalized anxiety disorder under DSM-5 and ICD-11
Classification: one of the anxiety disorders, occurring in childhood and adulthood
“Anxiety disorders comprise separation anxiety and selective mutism (occurring primarily in childhood; between the ages of 4 years and 18 years), specific phobias, social anxiety disorder, and generalised anxiety disorder (occurring in childhood as well as in adulthood), as well as panic disorder and agoraphobia (occurring primarily in adulthood; from the age of 18 years and older).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fear is a conscious feeling evoked by threat or impending danger, whereas anxiety involves anticipation of real or imagined future threat or danger.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic history: from DSM-III to the 6-month duration criterion
Heritability: family and twin studies
“The calculated summary odds ratios ranged from 4 to 6, depending on the disorder. Only for panic disorder and generalized anxiety disorder could the authors identify more than one large-scale twin study for meta-analysis. These yielded heritabilities of 0.43 for panic disorder and 0.32 for generalized anxiety disorder. For panic disorder, the remaining variance in liability could be attributed primarily to nonshared environment. For generalized anxiety disorder, this was true for men, but for women, a potentially significant role for common familial environment was also seen.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Heritability of anxiety disorders can vary, but heritability estimates converge to rates of between around 35% for generalised anxiety disorder and around 50% for social anxiety disorder, panic disorder, and agoraphobia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mode of inheritance is complex, with many genetic variants of small effect interacting with, or adding to, other (presumably non-shared environmental) risk factors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, genome-wide association studies showed a high genetic correlation (rG>0·6) among people with anxiety, depression, and neuroticism,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is estimated that genes contribute 30% to 50%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“to the development of an anxiety disorder. Conversely, development of an anxiety disorder due to non-genetic factors is approximately 50% to 70%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Common genetic variants: genome-wide association meta-analysis of 122,341 cases of major anxiety disorders
“The major anxiety disorders (ANX; including generalized anxiety disorder, panic disorder and phobias) are highly prevalent, often onset early and cause substantial global disability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Here, we present a genome-wide association meta-analysis comprising 122,341 European ancestry ANX cases and 729,881 controls. We identified 58 independent genome-wide significant risk variants and 66 genes with robust biological support.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As predicted by twin studies, we found substantial genetic correlation between ANX and depression, neuroticism and other internalizing phenotypes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The SNP-based heritability estimated at 10.1% captures approximately one-quarter of the broad-sense heritability from twin studies of adult ANX” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Common genetic variants: UK Biobank genome-wide association study of lifetime anxiety disorder
“Anxiety disorders are common, complex psychiatric disorders with twin heritabilities of 30–60%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The liability scale common variant heritability estimate for Lifetime Anxiety Disorder was 26%, and for Current Anxiety Symptoms was 31%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Anxiety showed significant positive genetic correlations with depression and insomnia as well as coronary artery disease, mirroring findings from epidemiological studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Common genetic variants: Million Veteran Program genome-wide association study of GAD-2 score
Environmental risk factors: adverse life events and parenting
“The development of GAD is associated with unexpected negative life events (Nordahl et al. 2010), maltreatment (Moffitt et al. 2007), and loss (Kendler et al. 2003).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition to one-time events, as outlined below, those with GAD have increased likelihood of negative experiences that are more chronic in nature, including ongoing abuse, parental rejection, inconsistent parenting, and parental invalidation (Cougle et al. 2010, Moffitt et al. 2007).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“GAD symptoms in children and adolescents have also been associated with harsh parental discipline and parenting characterized by strict rules and high expectations (Shanahan et al. 2008) as well as parental overprotection (Beesdo et al. 2010, Nordahl et al. 2010).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Environmental factors that influence the risk for anxiety disorders at multiple timepoints include various stressful life experiences and parenting practices, including childhood trauma, separation from attachment figures, and forms of overprotective parenting that limit children’s opportunities to encounter frightening circumstances in ways that facilitate mastery.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sociodemographic correlates: NESARC, United States adults
“Data are taken from a large (n=43093) representative sample of the adult USA population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Being female, middle-aged, widowed/separated/divorced, and low income increased risk, while being Asian, Hispanic, or Black decreased risk.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor statement on causes of generalized anxiety disorder
Epidemiology
Incidence of Generalized anxiety disorder
United States diagnosed incidence: Komodo Healthcare Map claims, adults, 2020 to 2023
“We estimated the prevalence and incidence of diagnosed GAD among adults in the U.S. healthcare system using payer-complete closed claims data from the Komodo Healthcare Map™ database from January 1, 2020 to December 31, 2023. Patients with GAD were identified using ICD-10 code F41.1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The numerator consisted of patients with a new GAD diagnosis in the index year and no documented GAD diagnosis during the prior two calendar years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The annual incidence of GAD in the U.S. among adults engaging with the healthcare system ranged from 2.1% to 2.3%, using a 2-year pre-index lookback to confirm no prior diagnosis and identify newly diagnosed cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Claims data represent treatment-seeking patients, which may limit generalizability to a broader population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States first incidence of DSM-IV generalized anxiety disorder: NESARC Waves 1 and 2
“One-year incidence rates of DSM-IV substance, mood and anxiety disorders were highest for alcohol abuse (1.02) alcohol dependence (1.70), major depressive disorder (MDD: 1.51) and generalized anxiety disorder (GAD: 1.12).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 1-year incidence rates and 1-year incidence rates per 100 py were very similar given the small numbers of incident cases (Table 1), and are reported hereinafter as rates per 100 py at risk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only the Netherlands survey reported incidence of DSM-III-R specific phobia (2.20) and generalized anxiety disorder (GAD) (0.72).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Predictors of incident generalized anxiety disorder: NESARC
“Women were at increased risk of all incident anxiety disorders except social phobia (Table 4). Risks of incident panic disorder and social phobia were greater among respondents 20-to-54 years-old, whereas increased risks of specific phobia and GAD were only observed among 30-to-54 year-olds. Except for specific phobia, the risks of incident anxiety disorders were increased among respondents with incomes ≤ $19,999/year. The risk of incident GAD was also greater among respondents who were separated/divorced/widowed and lower among Hispanics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increased risk of incident GAD was observed among respondents with baseline MDD, bipolar I, panic disorder, and social phobia, and with schizotypal, borderline, and narcissistic PDs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One of the most interesting findings of this study was the reciprocal temporal relationships between MDD and GAD, and GAD and panic disorder.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at onset: NCS-R and NCS-A, United States
“First, median AOO (i.e. the 50th percentile on the AOO curves) is earliest for the phobias and SAD (ages 15–17) and latest for PD (age 23), MDE (age 25), and GAD (age 30).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MDE, GAD, and PD, at the other extreme, have IQRs in the range 23–27 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Indeed, a comparison of cumulative lifetime prevalence estimates as of age 64 with those as of age 17 in Figures 2 and 3 shows that an estimated 69–74% of all lifetime cases of MDE, GAD, and PD have first onsets in the age range 18–64.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at onset: meta-analysis of 192 epidemiological studies
| Measure | Generalised anxiety disorder |
|---|---|
| No of samples | “24”View highlighted excerpt for this quote |
| Peak age at onset (years) | “15.5”View highlighted excerpt for this quote |
| Proportion onset by 14 years | “8.6%”View highlighted excerpt for this quote |
| Proportion onset by 18 years | “20.4%”View highlighted excerpt for this quote |
| Proportion onset by 25 years | “33.0%”View highlighted excerpt for this quote |
| 25th percentile age at onset (years) | “20”View highlighted excerpt for this quote |
| Median age at onset (years) | “32”View highlighted excerpt for this quote |
| 75th percentile age at onset (years) | “42”View highlighted excerpt for this quote |
Global incidence of anxiety disorders (all types combined): Global Burden of Disease Study 2019
“Globally, the estimated newly-diagnosed anxiety disorders patients increased from 31.13 (95% UI: 25.08, 37.92) million in 1990 to 45.82 (95% UI: 37.14, 55.62) million in 2019, with a relatively stable ASIR of about 5.8 (95% UI: 4.68, 7.03) cases per 1000 population over the past 30 years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence rate of anxiety disorders rose to a peak at age 10–14 years, remained relatively high level until age 40–44 years, and dropped substantially afterward among both sexes in 2019” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
High-income North America incidence of anxiety disorders (all types combined): Global Burden of Disease Study 2019
| Region | Incident cases in 2019, millions (95% UI) | Age-standardised incidence rate per 1000 in 2019 (95% UI) |
|---|---|---|
| High-income North America | “2.86 (2.31, 3.52)”View highlighted excerpt for this quote | “8.06 (6.44, 9.87)”View highlighted excerpt for this quote |
Prevalence of Generalized anxiety disorder
United States past-year prevalence by clinical interview: MDPS, adults aged 18 to 65, 2020 to 2022
United States diagnosed prevalence: Komodo Healthcare Map claims, adults, 2020 to 2023
“Projected annual prevalence increased from 5.4% in 2020–6.6% in 2023, with a 3-year prevalence of 10.3% over the 2021–2023 period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, more than one in ten adults met criteria for GAD over a three-year period, exceeding lifetime prevalence estimates from prior general population studies, which have ranged from approximately 5% to almost 8%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When this exclusion criterion was removed, the estimated one-year prevalence of GAD in 2023 increased from 6.6% in the base case to 7.2%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Demographic analyses across each 1-year time period reveal that females appeared in GAD claims data at more than twice the rate of males.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States past-year and lifetime prevalence: NCS-R, adults, 2001 to 2003
United States 12-month prevalence and severity: NCS-R, adults (n=9282)
| Generalized anxiety disorder, 12-month | Total, % (se) | Serious, % (se) | Moderate, % (se) | Mild, % (se) |
|---|---|---|---|---|
| NCS-R | “3.1 (0.2)”View highlighted excerpt for this quote | “32.3 (2.9)”View highlighted excerpt for this quote | “44.6 (4.0)”View highlighted excerpt for this quote | “23.1 (2.9)”View highlighted excerpt for this quote |
United States lifetime prevalence and lifetime morbid risk: NCS-R and NCS-A, ages 13 and older
“The LMR/12‐month prevalence estimates ranked by frequency are as follows: major depressive episode: 29.9%/8.6%; specific phobia: 18.4/12.1%; social phobia: 13.0/7.4%; post‐traumatic stress disorder: 10.1/3.7%; generalized anxiety disorder: 9.0/2.0%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The less common anxiety disorders include GAD (4.3%), panic disorder with or without agoraphobia (PD; 3.8%), agoraphobia with or without panic disorder (2.5%), and OCD (2.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These discrepancies might reflect the fact that GAD has a chronic‐episodic course reflected in intermediate prevalence ratios for all three age groups (roughly 35–50% of lifetime cases in episode in the 12 months before interview)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States 12-month and lifetime prevalence: NESARC, adults
United States adolescent lifetime prevalence: NCS-A, ages 13 to 18, 2001 to 2004
United States primary care prevalence: 15 clinics, 2004 to 2005
“15 U.S. primary care clinics.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 965 patients, 19.5% (95% CI, 17.0% to 22.1%) had at least 1 anxiety disorder, 8.6% (CI, 6.9% to 10.6%) had posttraumatic stress disorder, 7.6% (CI, 5.9% to 9.4%) had a generalized anxiety disorder” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cross-national prevalence of DSM-5 generalized anxiety disorder: World Mental Health Surveys, 26 countries, 2001 to 2012
“Across all surveys, the combined lifetime prevalence of GAD was 3.7%, 12-month prevalence was 1.8%, and 30-day prevalence was 0.8% (Table 1). Lifetime prevalence estimates varied widely across countries, ranging from less than 1% of the populations of Nigeria and Shenzhen, China, to approximately 8% of the populations of Australia, New Zealand, and the United States. Prevalence increased with economic development: lifetime estimates (SE) were lowest in low-income (1.6% [0.1%]), moderate in middle-income (2.8% [0.1%]), and highest in high-income (5.0% [0.1%]) countries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States prevalence of DSM-5 generalized anxiety disorder: World Mental Health Surveys, US survey (n=9282)
| Country | Lifetime prevalence, No. (%) [SE] | 12-mo prevalence, No. (%) [SE] | 30-d prevalence, No. (%) [SE] | 12-mo prevalence among lifetime cases, No. (%) [SE] |
|---|---|---|---|---|
| United States | “752 (7.8) [0.3]”View highlighted excerpt for this quote | “394 (4.0) [0.2]”View highlighted excerpt for this quote | “157 (1.6) [0.2]”View highlighted excerpt for this quote | “394 (52.1) [1.8]”View highlighted excerpt for this quote |
Sponsor-stated number of United States adults with generalized anxiety disorder
Anxiety symptoms measured by GAD-7 (symptoms, not diagnosis): NHIS, adults, 2019
Anxiety symptoms measured by GAD-7 (symptoms, not diagnosis): NHIS, adults, 2019 and 2022
“During 2022, about one in five adults age 18 and older experienced any symptoms of anxiety (18.2%) or symptoms of depression (21.4%) in the past 2 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A significant increase was seen in the percentage of adults with anxiety symptoms (from 15.6% to 18.2%, respectively) and depression symptoms (from 18.5% to 21.4%, respectively) between 2019 and 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Positive GAD-7 screen, score of 10 or more (symptoms, not diagnosis): CLIMB cohort, United States adults, 2020 to 2022
“Using a longitudinal, nationally representative study of US adults, we used generalized estimating equations to estimate the burden of positive screen for GAD (GAD-7 score ≥ 10) over time. The final sample included 1270 adults at least 18 years old who completed the COVID-19 and Life Stressors Impact on Mental Health and Well-being (CLIMB) Study, with data collected in spring 2020, 2021, and 2022. The national prevalence of positive screen for GAD decreased from 24.4% in 2020 to 21.3% in 2022 (P < .05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Self-reported past-month nervousness (single item, not diagnosis): NSDUH, United States adults, 2008 to 2018
“This variable was assessed with the item” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“how often did you feel nervous during the past 30 days” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Anxiety increased from 5.12% in 2008 to 6.68% in 2018 (p < 0.0001) among adult Americans. Stratification by age revealed the most notable increase from 7.97% to 14.66% among respondents 18–25 years old (p < 0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global prevalence of anxiety disorders (all types combined): Global Burden of Disease Study 2019
“The accumulated anxiety disorder patients worldwide increased from 194.92 (95% UI: 165.10, 231.23) million in 1990 to 301.39 (95% UI: 252.63, 356.00) million in 2019, and kept a stable ASPR with around 37.8 (95% UI: 31.94, 44.77) per 1000 population during the period” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global prevalence of anxiety disorders (all types combined) in 2020: change attributed to the COVID-19 pandemic
Natural history, survival, and mortality
Age of onset: DSM-5 generalized anxiety disorder in the World Mental Health Surveys
“Onset before puberty was rare in these surveys, with only 5% of cases developing by age 13 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was a gradual, steady accumulation of new cases over the lifespan, with 25% of all cases emerging by 25 years, 50% of the cases emerging by 39 years, and 75% of the cases emerging by 53 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although the AOO distribution was shifted earlier for high-income countries (median AOO, 36 years) relative to middle- and low-income countries (median AOO, 43 years for both), the distributions were substantively similar across country groups” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recovery and recurrence over 12 years: Harvard/Brown Anxiety Disorders Research Program
“Survival analyses revealed an overall chronic course for the majority of the anxiety disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In comparison, patients with generalized anxiety disorder, panic disorder with agoraphobia, and social phobia had much lower probabilities of achieving recovery over 12 years of follow-up (probabilities of 0.58, 0.48, and 0.37, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The probability of having a recurrence of social phobia was 0.39 over 12 years, and the probability of recurrence in patients who had recovered from generalized anxiety disorder was 0.45 at the end of the 12 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average time spent in an illness episode during the study period was 80% for social phobia, 78% for panic disorder with agoraphobia, and 74% for generalized anxiety disorder.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These data depict the anxiety disorders as insidious, with a chronic clinical course, low rates of recovery, and relatively high probabilities of recurrence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Remission in the first two years: Harvard Anxiety Research Program
“Analysis of the 164 patients with GAD participating in the Harvard Anxiety Research Program.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The likelihood of remission was 0.15 after one year and 0.25 after two years. The probability of becoming asymptomatic from all psychiatric symptoms was only 0.08.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Likelihood of remission for GAD and any other comorbid condition after one year was half the annual remission rate for GAD alone.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Persistence of lifetime cases: World Mental Health Surveys
“Generalized anxiety disorder typically begins in adulthood and persists over time, although onset is later and clinical course is more persistent in lower-income countries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Generalized anxiety disorder was more persistent in low-income (59.5%) and middle-income (56.1%) countries than in high-income countries (45.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Around the world, persistence was higher for earlier-onset GAD cases, for individuals with lower educational levels and family income, and for those not employed outside the home (ie, Other status, homemaker)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Two-year remission and chronic recurrent course: Lancet seminar
“Epidemiological studies show a relatively high ratio of 1 year to lifetime prevalence for anxiety disorders, indicative of a chronic recurrent nature.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with only one anxiety disorder, 2 year remission rates were around 70% for panic disorder without agoraphobia and generalised anxiety disorder, decreasing to 50–55% for social anxiety disorder and panic disorder with agoraphobia and 43% for those with multiple anxiety disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Course over 40 years of follow-up: hospital-admitted cohort in Madrid
“Patients admitted with the diagnosis of anxiety states ('anxious thymopathy' ) to the Lopez Ibor Neuropsychiatric Research Institute between 1950 and 1961 were examined between 1984 and 1988 (n = 65).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At first and second examinations 20% and 17% of subjects were diagnosed as GAD. Improvement was observed in 83%. GAD tended to disappear around age 50, but was replaced by somatization disorders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Lack of regular treatment compliance, female sex, and onset of GAD before age 25 were variables associated with a worse outcome.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Remission, recurrence, and prognosis: guideline and review statements
Mortality: Danish total-population cohort
“In total, 1066 (2.1%) people with anxiety disorders died during an average follow-up of 9.7 years. The risk of death by natural and unnatural causes was significantly higher among individuals with anxiety disorders (natural mortality rate ratio (MRR) = 1.39, 95% CI 1.28–1.51; unnatural MRR = 2.46, 95% CI 2.20–2.73) compared with the general population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of those who died from unnatural causes, 16.5% had comorbid diagnoses of depression (MRR = 11.72, 95% CI 10.11–13.51).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The risk for natural death was increased among patients with acute stress reaction, generalised anxiety disorder, panic disorder and social phobia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the risk for unnatural death was more than doubled in patients with acute stress reaction, generalised anxiety disorders, post-traumatic stress disorder and social phobia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Mortality rate ratio (95% CI), 2002 to 2011 | Generalised anxiety disorder |
|---|---|
| All causes | “1.62 (1.35–1.93)”View highlighted excerpt for this quote |
| Unnatural causes | “2.55 (2.00–3.19)”View highlighted excerpt for this quote |
| Natural causes | “1.64 (1.36–1.95)”View highlighted excerpt for this quote |
Suicidal ideation, attempts, and suicide: meta-analysis of 42 observational studies
“Forty-two observational studies were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to those without anxiety, patients with anxiety were more likely to have suicidal ideations (OR = 2.89, 95% CI: 2.09, 4.00), attempted suicides (OR = 2.47, 95% CI: 1.96, 3.10), completed suicides (OR = 3.34, 95% CI: 2.13, 5.25), or have any suicidal behaviors (OR = 2.85, 95% CI: 2.35, 3.46).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The increase in the risk of suicide was demonstrated for each subtype of anxiety except obsessive-compulsive disorder (OCD). The quality of this evidence is considered low to moderate due to heterogeneity and methodological limitations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Suicidal thoughts and behaviors: meta-analysis of longitudinal prediction studies
“Results indicated that anxiety is a statistically significant, yet weak, predictor of suicide ideation (OR=1.49, 95% CI: 1.18, 1.88) and attempts (OR=1.64, 95% CI: 1.47, 1.83), but not deaths (OR=1.01, 95% CI: 0.87, 1.18).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Diagnoses of GAD, specific phobia, and social anxiety disorder were also significant predictors of suicide ideation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Agoraphobia, GAD, OCD, somatic symptom disorder, and specific phobia did not reach the level of statistical significance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of note, only 4 suicide ideation prediction cases were used to generate overall ORs for PTSD, specific phobia, and social anxiety disorder, and only 2 cases were used for GAD, thereby limiting the conclusions we can draw from this set of analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Suicidal ideation by symptom severity: sponsor-funded National Health and Wellness Survey analysis
Pathophysiology
Threat-response circuitry: anxiety disorders
“This research suggests that perturbed threat responding in anxiety disorders involves dysfunction in the circuitry that supports core psychological processes, such as attention, emotion, learning, and memory.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Many brain imaging studies have examined the structure of regions that basic neuroscience implicates in threat responding, showing structural alterations in anxiety disorders within medial temporal, prefrontal cortex, and cingulate regions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With functional MRI, patients who are anxious have an altered response in temporal and prefrontal brain regions, which has also been shown in functional MRI research regarding attention.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When people are exposed to stressors, such as public speaking, scary pictures, or painful stimulation, studies generally report increased stress responses in people with anxiety disorders versus controls across many measures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For peripheral measures, rarely do effect sizes exceed a Cohen’s d of 0·50, indicating that these are not useful biomarkers that currently guide diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Amygdala subregion connectivity and a compensatory frontoparietal network: resting-state fMRI
“In GAD patients, BLA and CMA connectivity patterns were significantly less distinct, and increased gray matter volume was noted primarily in the CMA. Across the subregions, GAD patients had increased connectivity with a previously characterized frontoparietal executive control network and decreased connectivity with an insula- and cingulate-based salience network.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In GAD, we find evidence of an intra-amygdalar abnormality and engagement of a compensatory frontoparietal executive control network, consistent with cognitive theories of GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Amygdala-prefrontal connectivity and physiological arousal
“The disrupted coordination of brain activity has been proposed as one of the core neurobiological features of GAD,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Findings suggest that across adolescence and adulthood, decreased connectivity between the amygdala and PFC is associated with the diagnosis of GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In general, the psychophysiological literature demonstrates that individuals with GAD are in a more physiologically dysregulated state (e.g., low HRV, high heart rate, higher skin conductance levels) at baseline relative to controls” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Yet, this hyperarousal psychophysiological pattern in GAD is not universally observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Task-based affective neuroimaging: variable limbic and prefrontal findings
“Studies provide evidence for variable presence and directionality of BOLD abnormalities in limbic and prefrontal regions during reactivity to, regulation of, and learning from emotional cues.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We propose that the cardinal symptom of GAD—worry—predominantly reflects stimulus-independent mental processes that impose abnormal, inflexible functional brain configurations, ie, the overall pattern of information transfer among behaviorally relevant neural circuits at a given point in time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Brain structure: ENIGMA-Anxiety mega-analysis, 28 sites
“The main analysis (1020 individuals with GAD and 2999 healthy controls) included random slopes per site and random intercepts per scanner.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The main analysis showed no effect of GAD on brain structure, nor interactions involving GAD, age, or sex.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Emotional hyperreactivity and worry: Contrast Avoidance model
“A synthesis of these data points to a central role of emotional hyperreactivity, sensitivity to contrasting emotions, and dysfunctional attempts to cope with strong emotional shifts via worry. Consistent with the Contrast Avoidance model, evidence shows that worry evokes and sustains negative affect, thereby precluding sharp increases in negative emotion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consistent with this vulnerability, functional magnetic resonance imaging studies of GAD cumulatively suggest hyperresponsivity of the amygdala, the limbic structure that mediates negatively valenced affective reactions, and fear in particular (Schienle et al. 2011).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neurotransmitter systems: serotonergic and noradrenergic activity
Serotonin receptor subtypes: 5-HT1A and 5-HT2A signaling in anxiety
“Like impulsivity and aggression, anxiety appears to be negatively modulated by 5-HT1AR stimulation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The serotonin 2A receptor has also been implicated in anxiety. Serotonin 2A receptor knock-out mice display reduced anxiety which is normalised when its functioning is recovered (Weisstaub et al., 2006). These findings suggest that 5-HT2AR signalling has an anxiogenic effect that is opposite to the anxiolytic effect of postsynaptic 5-HT1AR activation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, whereas postsynaptic 5-HT1AR activation appears to moderate anxiety and stress, the effect of 5-HT2AR activation is more complex (Carhart-Harris et al., 2016c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serotonin 2A receptor binding and trait anxiety: PET in healthy volunteers
“Neuroticism correlated positively with frontolimbic serotonin 2A receptor binding [r(79) = .24, p = .028]. Post hoc analysis of the contributions from the six constituent traits of neuroticism showed that the correlation was primarily driven by two of them: vulnerability and anxiety.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
GABAergic signaling: genetic risk for major anxiety disorders
Inflammation: peripheral inflammatory markers
“CRP was significantly higher in people with GAD compared with controls, with a small effect size (Cohen’s d=0.38, 0.06–0.69), comparable with that reported in schizophrenia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is preliminary evidence to suggest an inflammatory response in GAD, but it remains unclear whether inflammatory cytokines play a role in the aetiology.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor statement on brain circuitry in generalized anxiety disorder
Diagnosis
DSM-5 diagnostic criteria for generalized anxiety disorder
Clinical diagnosis without a biomarker
“Because no blood, genetic, or imaging biomarkers exist, diagnosis rests on mental-state history and examinations, which should therefore be sufficiently monitored by every primary care practitioner.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Categorical diagnostic criteria are clinically useful, but boundaries between anxiety disorders and normative anxiety are often ill-defined. Recognition of distinctions requires clinical judgement of severity, duration, persistence, and, importantly, degree of distress and impairment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Structured interviews and rating scales
“Validated, structured, or semi-structured clinical interviews, such as the DSM-5-based or ICD-11-based composite international diagnostic interview9 or structured clinical interview for DSM disorders,10 can assist in correct diagnostics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To determine the severity of anxiety disorders and monitor treatment, continuous clinician-rated scales include, for example, the Hamilton Anxiety Scale.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Standardised diagnostics and assessments for outcome monitoring are part of evidence-based care, could prevent underdiagnosis, and lead to effective treatments. However, these diagnostics and assessments are still not widely used in clinical practice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Identification and assessment: NICE clinical guideline CG113
Exclusion of medical causes and differential diagnosis
“For any patient presenting with increased pathological anxiety, a thorough psychiatric and somatic evaluation should consider whether symptoms reflect other health conditions or effects of substance or medication use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Laboratory assessment of plasma thyroid-stimulating hormone” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Screening of adults: USPSTF recommendation, June 2023
Screening of adults: AFP review statement, August 2022, before the USPSTF recommendation of June 2023
Accuracy of the GAD-7 and GAD-2 screening instruments
“A criterion-standard study was performed in 15 primary care clinics in the United States from November 2004 through June 2005.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A cut point was identified that optimized sensitivity (89%) and specificity (82%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 12 samples were identified involving 5223 participants; 11 samples provided data on the accuracy of the GAD-7 for identifying generalized anxiety disorder (GAD).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Pooled sensitivity and specificity values appeared acceptable at a cutoff point of 8 [sensitivity: 0.83 (95% CI 0.71-0.91), specificity: 0.84 (95% CI 0.70-0.92)] although cutoff scores 7-10 also had similar pooled estimates of sensitivity/specificity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Pooled sensitivity and specificity values appeared acceptable at a cutoff of 3 [sensitivity: 0.76 (95% CI 0.55-0.89), specificity: 0.81 (95% CI 0.60-0.92)].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Detection and treatment gaps in primary care
“Of the 965 patients, 19.5% (95% CI, 17.0% to 22.1%) had at least 1 anxiety disorder, 8.6% (CI, 6.9% to 10.6%) had posttraumatic stress disorder, 7.6% (CI, 5.9% to 9.4%) had a generalized anxiety disorder” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Many patients (41%) with an anxiety disorder reported no current treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Receiver-operating characteristic curve analysis showed that both the GAD-7 scale and its 2 core items (GAD-2) performed well (area under the curve, 0.80 to 0.91) as screening tools for all 4 anxiety disorders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Cognitive symptoms: excessive, uncontrollable worry
Psychological symptoms: restlessness, irritability, and difficulty concentrating
Somatic symptoms: muscle tension, fatigue, and autonomic complaints
“Being easily fatigued.” (opens the source at this quote in a new tab)
“Muscle tension.” (opens the source at this quote in a new tab)
Sleep symptoms: difficulty falling or staying asleep, or restless sleep
Functional impairment: social, occupational, and role functioning
“Respondents with 12-month GAD reported a mean (SE) of 41.2 days (2.4) out of role due to GAD in the past year. Half (50.6%) of the 12-month cases reported severe functional impairment resulting from GAD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The rate of severe impairment was lower yet still substantial (35.3%) among individuals with GAD who had no comorbid disorders” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Respondents rated the extent of interference with home management, work, close relationships, and social life on separate 0-to-10 scales.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increasing scores on the scale were strongly associated with multiple domains of functional impairment (all 6 Medical Outcomes Study Short-Form General Health Survey scales and disability days).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, GAD and depression symptoms had differing but independent effects on functional impairment and disability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Disability and impairment in pure GAD were equivalent to pure mood disorders, but significantly greater than in pure substance use, and other anxiety and personality disorders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
| Generalized anxiety disorder, 12-month cases (NCS-R) | Quoted value, % (se) |
|---|---|
| Twelve-month prevalence | “3.1 (0.2)”View highlighted excerpt for this quote |
| Serious | “32.3 (2.9)”View highlighted excerpt for this quote |
| Moderate | “44.6 (4.0)”View highlighted excerpt for this quote |
| Mild | “23.1 (2.9)”View highlighted excerpt for this quote |
Long-term morbidity
Psychiatric comorbidity: World Mental Health Surveys
“Lifetime comorbidity is high (81.9% [0.7%]), particularly with mood (63.0% [0.9%]) and other anxiety (51.7% [0.9%]) disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The single most common comorbid condition was major depressive disorder, which was found in 52.6%(0.9%) of lifetime cases and 40.9%(1.3%) of 12-month cases of GAD worldwide.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Major depressive episode: onset after generalized anxiety disorder in the National Comorbidity Survey follow-up
“Data were analyzed from the nationally representative two-wave panel sample of 5001 respondents who participated in the 1990-2 National Comorbidity Survey (NCS) and the 2001-03 NCS follow-up survey.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline MDE significantly predicted subsequent GAD onset but not persistence. Baseline GAD significantly predicted subsequent MDE onset and persistence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The associations of each disorder with the subsequent onset of the other attenuated with time since onset of the temporally primary disorder, but remained significant for over a decade after this onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The OR of temporally primary MDE predicting subsequent first onset of GAD is 2.7 (Table 1, Part I). The OR of temporally primary GAD predicting subsequent first onset of MDE is 3.2 (Table 1, Part II).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Substance use, mood, anxiety, and personality disorders: National Epidemiologic Survey on Alcohol and Related Conditions
“GAD was highly co-morbid with substance use, and other anxiety, mood, and personality disorders. Co-morbidity in GAD was not substantially greater than for most other Axis I and II disorders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals co-morbid for GAD and each mood disorder were more disabled than those with pure forms of GAD or each mood disorder.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Comorbidity and the course of anxiety disorders
“Symptoms are generally not pathognomonic of individual anxiety disorders, and anxiety disorder comorbidity is substantial: 48–68% of adults with one anxiety disorder fulfil the criteria for another concurrent anxiety disorder.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“people with multiple disorders have higher severity, disability, and a poorer disease course compared with people who have a single anxiety disorder.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Anxiety and depression comorbidity signifies higher disorder severity, burden, and chronicity compared with individual disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall clinical course was worsened by several comorbid psychiatric conditions, including major depression and alcohol and other substance use disorders, and by comorbidity of generalized anxiety disorder and panic disorder with agoraphobia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with generalized anxiety disorder, those with comorbid panic disorder with agoraphobia had a significantly lower likelihood of recovering from generalized anxiety disorder, compared to those without comorbid panic disorder with agoraphobia (risk ratio=0.67, p<0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular disease: incident disease in meta-analyses of population cohorts
“The meta-analysis comprised 37 papers (n = 1 565 699). The follow-up ranged from 1 to 24 years. Anxiety was associated with a 52% increased incidence of CVD (hazard ratio = 1.52, 95% CI 1.36-1.71). The risk seemed independent of traditional risk factors and depression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty studies reporting on incident CHD comprised 249,846 persons with a mean follow-up period of 11.2 years. Anxious persons were at risk of CHD (hazard ratio [HR] random: 1.26; 95% confidence interval [CI]: 1.15 to 1.38; p < 0.0001) and cardiac death (HR: 1.48; 95% CI: 1.14 to 1.92; p = 0.003), independent of demographic variables, biological risk factors, and health behaviors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular events in stable coronary heart disease: Heart and Soul Study
“One thousand fifteen outpatients with stable CHD followed up for a mean (SD) of 5.6 (1.8) years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The age-adjusted annual rate of cardiovascular events was 9.6% in the 106 participants with GAD and 6.6% in the 909 participants without GAD (P = .03).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After adjustment for demographic characteristics, comorbid conditions (including major depressive disorder), cardiac disease severity, and medication use, GAD remained associated with a 62% higher rate of cardiovascular events (hazard ratio, 1.62; 95% confidence interval, 1.11-2.37; P = .01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Other somatic conditions
“with emerging evidence of increased onset risk of other somatic conditions, including stroke, diabetes, arthritis, and lung disease than in the general population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with diverse somatic illnesses, including cardiovascular, respiratory, or musculoskeletal disease, have an increased risk of comorbid anxiety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complications listed in a clinical review
“Drug or alcohol use disorder” (opens the source at this quote in a new tab)
“Gastrointestinal tract problems” (opens the source at this quote in a new tab)
“Social isolation” (opens the source at this quote in a new tab)
“Issues functioning at work or school” (opens the source at this quote in a new tab)
Multimorbidity and depressive symptoms by symptom severity: sponsor-funded National Health and Wellness Survey analyses
Burden of Generalized anxiety disorder
Humanistic burden and health-related quality of life
Health-related quality of life by GAD symptom severity: 2022 US National Health and Wellness Survey
Health-related quality of life in likely undiagnosed and diagnosed GAD: 2022 US National Health and Wellness Survey
“A retrospective, cross-sectional observational study was conducted using data from the 2022 US National Health and Wellness Survey (N = 75,261 adults).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adults with likely GAD experienced significantly lower HRQoL, greater work productivity loss, activity impairment, emergency room visits, hospitalizations, and healthcare costs (both direct and indirect), than those with diagnosed GAD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adults with GAD-whether likely and undiagnosed or diagnosed-had significantly lower HRQoL and higher work productivity loss, activity impairment, healthcare resource use, and healthcare costs than those without GAD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Degree of impairment among U.S. adults with past-year GAD
Functional impairment and health-related quality of life: systematic review of studies in North America and Europe
“GAD was associated with increased impairments in psychosocial functioning, role functioning, work productivity and health-related quality of life (HRQL).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The HRQL impairments were comparable with those associated with depression or panic disorder.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with GAD and co-morbid depression reported significantly greater impairment in HRQL than did those with either disorder alone.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Role functioning and quality of life compared with other mental disorders: review of 34 studies
“A review of 34 studies reporting original quantitative data on associations between GAD and role functioning, QOL, and/or economic costs was undertaken.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Large representative studies showed that role impairments of pure GAD were similar in magnitude to those of pure MDD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Studies of DSM-IV disorders showed that QOL impairments of GAD were at least comparable in magnitude to those of MDD; studies of DSM-III-R disorders showed the opposite pattern.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life in anxiety disorders compared with nonclinical controls: meta-analysis
“Thirty-two patient samples from 23 separate studies (N=2892) were included in the analysis. The results yielded a large effect size indicating poorer quality of life among anxiety disorder patients vs. controls and this effect was observed across all anxiety disorders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“QOL domains of mental health and social functioning were associated with the highest levels of impairment among anxiety disorder patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Impairment in U.S. primary care patients with anxiety disorders
“Of the 965 patients, 19.5% (95% CI, 17.0% to 22.1%) had at least 1 anxiety disorder, 8.6% (CI, 6.9% to 10.6%) had posttraumatic stress disorder, 7.6% (CI, 5.9% to 9.4%) had a generalized anxiety disorder, 6.8% (CI, 5.3% to 8.6%) had a panic disorder, and 6.2% (CI, 4.7% to 7.9%) had a social anxiety disorder.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Each disorder was associated with substantial impairment that increased significantly (P < 0.001) as the number of anxiety disorders increased.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Many patients (41%) with an anxiety disorder reported no current treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Direct and indirect costs: 2022 US National Health and Wellness Survey, sponsor-funded
Healthcare resource use, adjusted: 2022 US National Health and Wellness Survey, sponsor-funded
Healthcare resource use, unadjusted, and payer survey: 2022 US National Health and Wellness Survey, sponsor-funded
Work productivity and activity impairment: 2022 US National Health and Wellness Survey, sponsor-funded
Healthcare resource use with and without co-occurring major depressive disorder: U.S. claims 2022 to 2024, sponsor-authored
U.S. health care spending on anxiety disorders, 2016
| Measure | Anxiety disorders |
|---|---|
| Spending rank among 154 health conditions | “21”View highlighted excerpt for this quote |
| Health care spending, 2016 $Billion (95% CI) | “42.4 (37.8-47.7)”View highlighted excerpt for this quote |
| Age 20 to 64 years, % of spending | “75.3”View highlighted excerpt for this quote |
| Public insurance, % of spending | “49.6”View highlighted excerpt for this quote |
| Private insurance, % of spending | “41.2”View highlighted excerpt for this quote |
| Out-of-pocket payments, % of spending | “9.2”View highlighted excerpt for this quote |
| Ambulatory care, % of spending | “55.7”View highlighted excerpt for this quote |
| Inpatient care, % of spending | “7.0”View highlighted excerpt for this quote |
| Prescribed pharmaceuticals, % of spending | “21.3”View highlighted excerpt for this quote |
Incremental direct medical expenditures for anxiety disorders: Medical Expenditure Panel Survey 2009 and 2010
“Data from the 2009 and 2010 Medical Expenditure Panel Survey (MEPS) were used to estimate the annual incremental healthcare expenditures associated with anxiety disorders, for the ambulatory adult population of the U.S.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The annual overall healthcare expenditure associated with anxiety disorders was estimated at $1657.52 per person (SE: $238.83; p<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Inpatient visits, prescription medications, and office-based visits together accounted for almost 93% of the overall cost.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Given the prevalence of self-reported anxiety disorders in MEPS, their total direct medical expenditure is estimated at approximately $33.71 billion in 2013 US dollars” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Out-of-pocket costs for anxiety disorders by insurance type: Medical Expenditure Panel Survey 2011 to 2014
“Using weighted nationally representative data from the 2011-2014 Medical Expenditure Panel Surveys, total OOP health care costs were assessed for all respondents who indicated that they had an anxiety disorder (N = 9985).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Average annual OOP costs among individuals with anxiety was $1152.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The highest OOP cost were incurred by individuals with private fee-for-service (FFS) insurance ($1356/year, 4.1% of annual income), while individuals enrolled in HMOs with dual Medicare/Medicaid had the lowest OOP cost ($129/year, 6.8% of annual income).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals without insurance had high OOP cost burden ($1309/year, 12.5% of annual income).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Healthcare costs before and after starting pharmacotherapy for GAD: U.S. claims 2003 to 2007
“Using a large US health insurance database, we identified all patients with evidence of GAD (ICD-9-CM diagnosis code 300.02) who initiated pharmacotherapy with medications commonly used to treat GAD (eg, selective serotonin reuptake inhibitors [SSRIs], venlafaxine, benzodiazepines) between 1/1/2003 and 12/31/2007.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 10,275 patients met all study inclusion criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean (SD) total healthcare costs increased from $4812 ($10,006) during pretreatment to $7182 ($22,041) during follow-up (p < 0.01); costs of GAD-related pharmacotherapy during follow-up were $420 ($485).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medical costs of GAD in primary care: systematic review
“GAD patients had significantly higher median medical costs than primary care patients without GAD (US $2375 versus $1448).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean annual medical cost of GAD was $2138 higher than for other anxiety disorders (mean $6475).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“GAD is associated with significant burden on patient functioning and well-being, leading to increased health care utilization and medical costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost-of-illness studies of anxiety disorders: systematic review and meta-analysis
“We identified 13 top-down and 11 bottom-up COI studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In top-down COI studies, direct costs of AD, on average, corresponded to 2.08% of health care costs and 0.22% of GDP, whereas indirect costs, on average, corresponded to 0.23% of GDP.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Subgroup analysis revealed an increase in direct costs by 1.60 (1.16-2.22; p = 0.005) for SAD and 2.60 (2.01-3.36; p < 0.001) for GAD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Societal cost of anxiety disorders in the United States, 1990
“We estimated the annual cost of anxiety disorders to be approximately $42.3 billion in 1990 in the United States, or $1542 per sufferer.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the $256 in workplace costs per anxious worker, 88% is attributable to lost productivity while at work as opposed to absenteeism.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Generalized anxiety disorder on families
Not applicable.
Economic impact of diagnostic testing
Not applicable.
Approaches to treatment
Current treatment options and standard of care
Psychological therapies
NICE guideline: low-intensity psychological interventions at step 2
“individual non-facilitated self-help” (opens the source at this quote in a new tab)
“individual guided self-help” (opens the source at this quote in a new tab)
“psychoeducational groups. [2011]” (opens the source at this quote in a new tab)
“be based on the treatment principles of CBT” (opens the source at this quote in a new tab)
NICE guideline: CBT or applied relaxation at step 3
WFSBP guideline: CBT as first-line psychotherapy
CANMAT guideline: efficacy of CBT and other psychological treatments
“Meta-analyses clearly demonstrate that CBT significantly reduces GAD symptoms and is markedly more effective than placebo or wait-list control conditions for GAD (Level 1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Few studies have compared CBT and pharmacotherapy alone in the same trial, but the magnitude of benefits appear to be comparable for both groups” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A meta-analysis of five trials found no significant differences between CBT and relaxation therapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, more recent studies suggest that applied relaxation has limited efficacy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CBT is an effective first-line option for the treatment of GAD and is as effective as pharmacotherapy. Internet-based and computer-based CBT have also demonstrated efficacy. Evidence does not support the routine combination of CBT and pharmacotherapy, but when patients do not benefit from CBT, a trial of pharmacotherapy is advisable, and vice versa.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CANMAT guideline: durability of benefit after psychological treatment
BAP guideline: psychological treatments compared with drug treatment
U.S. primary care review: psychotherapy techniques and comparative effectiveness
Meta-analysis of psychotherapy and medication trials: 79 randomized trials
“Seventy-nine randomized controlled trials (RCT) including 11,002 participants with a diagnosis of GAD were included in a meta-analysis that tested the efficacy of psychotherapies or medications for GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consistent with prediction, evidence-based psychotherapies outperformed control conditions on primary outcome measures at posttreatment with a medium to large effect size (g = 0.76, 95% CI: 0.61–0.91, p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within psychotherapy comparisons, pill placebo-controlled studies had the highest effect size (n = 3, g = 1.44, 95% CI: 0.94–1.94, p < 0.001), followed by WL controls (n = 22, g = 0.90, 95% CI: 0.73–1.08, p < 0.001), psychological placebo (n = 10, g = 0.47, 95% CI: 0.25–0.69, p < 0.001), and TAU (n = 5, g = 0.38, 95% CI: 0.05–0.71, p < 0.05;” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was evidence of publication bias in psychotherapy studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because medication studies had more placebo control conditions than inactive conditions compared to psychotherapy studies, effect sizes between the domains should not be compared directly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Meta-analysis of psychotherapy trials: 41 studies
“A total of 41 studies (with 2132 patients meeting diagnostic criteria for GAD) were identified through systematic searches in bibliographical databases, and were included in the meta-analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most studies examined the effects of cognitive behavior therapy (CBT).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The pooled effect of the 38 comparisons (from 28 studies) of psychotherapy versus a control group was large (g=0.84; 95% CI: 0.71-0.97) with low to moderate heterogeneity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There were some indications that CBT was also effective at follow-up and that CBT was more effective than applied relaxation in the longer term.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Meta-analysis across anxiety disorders: pre-post effect sizes of psychotherapies and medications
“Pre-post and treated versus control effect sizes (ES) were calculated for all evaluable randomized-controlled studies (n = 234), involving 37,333 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Medications were associated with a significantly higher average pre-post ES [Cohen's d = 2.02 (1.90-2.15); 28,051 patients] than psychotherapies [1.22 (1.14-1.30); 6992 patients; P < 0.0001].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Individual CBT was more effective than waiting list, psychological placebo and pill placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Pre-post ES for psychotherapies did not differ from pill placebos; this finding cannot be explained by heterogeneity, publication bias or allegiance effects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Selective serotonin reuptake inhibitors
NICE guideline: an SSRI as the first drug treatment, with sertraline first
NICE guideline: precautions with SSRIs
WFSBP guideline: SSRIs and SNRIs as first-line medications
CANMAT guideline: first-line, second-line, and third-line agents
“Agomelatine, duloxetine, escitalopram, paroxetine, paroxetine CR, pregabalin, sertraline, venlafaxine XR” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Citalopram, divalproex chrono, fluoxetine, mirtazapine, trazodone” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pharmacotherapeutic approaches should begin with one of the first-line options including an SSRI such as escitalopram, paroxetine, or sertraline,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BAP guideline: SSRIs as first-line pharmacological treatment
U.S. primary care review: SSRIs and SNRIs as first-line medications
FDA-approved GAD indication: escitalopram
FDA-approved GAD indication: paroxetine
FDA-approved agents and SSRIs without a GAD indication
“As an FDA-approved treatment for GAD in adults, immediate release paroxetine has been studied extensively and multiple studies support its efficacy in adults with GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Escitalopram has been approved by the FDA for the treatment of GAD in adults, and both escitalopram and citalopram have been evaluated in adults with GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a double-blind, placebo-controlled maintenance study, patients were treated with fixed-dose escitalopram (20 mg/day) over the course of 24–76 weeks, and re-randomization to placebo was associated with a significantly higher risk of relapse (OR: 4; 56% vs. 19%; log-rank test, p<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis: escitalopram, sertraline, fluoxetine, and paroxetine
“This analysis is based on 89 trials, which included 25 441 patients randomly assigned to 22 different active drugs or placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Primary outcomes were efficacy (mean difference [MD] in change in Hamilton Anxiety Scale Score) and acceptability (study discontinuations for any cause).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“escitalopram (MD -2·45, 95% CrI -3·27 to -1·63) were more efficacious than placebo with relatively good acceptability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mirtazapine, sertraline, fluoxetine, buspirone, and agomelatine were also found to be efficacious and well tolerated but these findings were limited by small sample sizes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Likewise, paroxetine and benzodiazepines were effective but also poorly tolerated when compared with placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Meta-analysis of SSRIs, SNRIs, and benzodiazepines against placebo: effect sizes and response rates
“A comprehensive literature search yielded 54 articles reporting 56 unique studies with 12,655 participants treated with either pill placebo (6,191 participants), SSRIs (16 trials, 2,712 participants), SNRIs (17 trials, 2,603 participants), or BZs (23 trials, 1,149 participants).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SSRIs (Hedges’ g = 0.33) and SNRIs (Hedges’ g = 0.36) demonstrated significantly lower effect sizes than BZs (Hedges’ g = 0.50).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Randomized-controlled trials suggest that 60-75% of patients respond to SSRIs, compared to 40-60% of patients receiving placebo, with similar response rates for SNRIs and BZs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Side effects of SSRIs during the initial weeks of treatment include nausea, dizziness, headaches, jitteriness, sleep difficulties, and gastrointestinal disturbances.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Escitalopram compared with paroxetine: adverse events and discontinuation
“A second and longer study (24 weeks) involved double-blind treatment with escitalopram (n=60; 10–20 mg/day) or paroxetine (n=61; 20–0 mg/day) and, while no differences were observed with regard to improvement in anxiety symptoms, treatment-emergent adverse events were more frequent in paroxetine-treated patients compared to those randomized to escitalopram (88.7% vs. 77.0%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, significantly fewer escitalopram- compared to paroxetine-treated patients discontinued due to adverse events (6.6% vs. 22.6%; p=0.02)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse reactions with escitalopram in adult GAD trials
Adverse reactions with paroxetine in adult GAD trials
Boxed warning and discontinuation syndrome in SSRI labeling
BAP guideline: adverse effects and discontinuation syndrome with SSRIs
Relapse after discontinuation: meta-analysis of relapse prevention trials, SSRI subgroup
| Subgroup | Number of studies | Odds ratio of relapse, placebo relative to continued antidepressant (95% CI) |
|---|---|---|
| All anxiety disorders | “28”View highlighted excerpt for this quote | “3.11 (2.48 to 3.89)”View highlighted excerpt for this quote |
| Generalised anxiety disorder (DSM-IV) | “6”View highlighted excerpt for this quote | “4.20 (2.42 to 7.28)”View highlighted excerpt for this quote |
| SSRI | “21”View highlighted excerpt for this quote | “2.86 (2.17 to 3.78)”View highlighted excerpt for this quote |
Serotonin-Norepinephrine reuptake inhibitors
NICE guideline: an alternative SSRI or an SNRI after sertraline
CANMAT guideline: duloxetine and venlafaxine XR as first-line agents
“an SNRI such as duloxetine or venlafaxine XR, or other antidepressant such as agomelatine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In head-to-head comparisons, the efficacy of SSRIs and SNRIs appear to be similar” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Some data suggest that escitalopram may be less effective than venlafaxine XR” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Efficacy of venlafaxine was similar to pregabalin in one RCT” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If response to optimal doses is inadequate or the agent is not tolerated, therapy should be switched to another first-line agent before considering second-line medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BAP guideline: SNRIs as alternative initial treatments
FDA-approved GAD indication: venlafaxine extended-release
Venlafaxine extended-release: HAM-A results of the four adult GAD studies
| Study and treatment group | LS mean change from baseline (SE) | Placebo-subtracted difference (95% CI) |
|---|---|---|
| Study 1, venlafaxine XR 75 mg | “-11.1 (0.95)” | “-1.5 (-3.8, 0.8)” |
| Study 1, venlafaxine XR 150 mg | “-11.7 (0.87)” | “-2.2 (-4.5, 0.1)” |
| Study 1, venlafaxine XR 225 mg | “-12.1 (0.81)” | “-2.6 (-4.9, -0.3)” |
| Study 1, placebo | “-9.5 (0.85)” | |
| Study 2, venlafaxine XR 75 mg | “-10.6 (0.82)” | “-2.6 (-4.6, -0.5)” |
| Study 2, venlafaxine XR 150 mg | “-9.8 (0.86)” | “-1.7 (-3.8, 0.3)” |
| Study 2, placebo | “-8.0 (0.73)” | |
| Study 3, venlafaxine XR 37.5 mg | “-13.8” | “-2.8 (-5.1, -0.6)” |
| Study 3, venlafaxine XR 75 mg | “-15.5” | “-4.6 (-6.9, -2.3)” |
| Study 3, venlafaxine XR 150 mg | “-16.4” | “-5.5 (-7.8, -3.1)” |
| Study 3, placebo | “-11.0” | |
| Study 4, venlafaxine XR 75-225 mg | “-13.4 (0.79)” | “- 4.7 (-6.6, -2.9)” |
| Study 4, placebo | “-8.7 (0.70)” |
FDA-approved GAD indication: duloxetine
Duloxetine: relapse prevention in responders
FDA approval history and response and remission with venlafaxine and duloxetine
“Venlafaxine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) that is FDA-approved for the treatment of GAD, MDD, panic disorder, and social anxiety disorder.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In adults with GAD, venlafaxine (75–225 mg/day) effectively reduces anxiety symptoms” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“and was the first FDA-approved antidepressant for the treatment of GAD in this age group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Response rates in patients receiving venlafaxine XR were 69% compared to 46% in patients randomized to placebo (p<0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These trials have recently been subjected to a meta-analysis which revealed superior remission rates for duloxetine (n=2,399, RR = 1.60, 95% CI: 1.43–1.80) and greater improvement in HAM-A scores (n=1,135, MD = 3.34, 95% CI: 2.37–4.32), while finding no differences in discontinuation rates between placebo and duloxetine” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis: duloxetine and venlafaxine
“Duloxetine (MD -3·13, 95% credible interval [CrI] -4·13 to -2·13)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“venlafaxine (MD -2·69, 95% CrI -3·50 to -1·89)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“were more efficacious than placebo with relatively good acceptability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
SNRIs compared with SSRIs: efficacy and sexual adverse effects
“SNRIs are very similar to SSRIs in their mechanism of action, side effects, and efficacy rates (Hedges’ g = 0.42, SD=0.12, p<0.0001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“though there is some evidence that SNRIs are associated with less sexual dysfunction side effects than SSRIs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse reactions and discontinuation with venlafaxine extended-release
Adverse reactions and discontinuation with duloxetine
Relapse after discontinuation: meta-analysis of relapse prevention trials, SNRI subgroup
| Subgroup | Number of studies | Odds ratio of relapse, placebo relative to continued antidepressant (95% CI) |
|---|---|---|
| SNRI | “3”View highlighted excerpt for this quote | “5.03 (1.31 to 19.40)”View highlighted excerpt for this quote |
Pregabalin
FDA-approved indications of pregabalin in the United States
European Union authorization for generalized anxiety disorder
CANMAT guideline: first-line agent and second-line adjunctive therapy
“The anticonvulsant pregabalin is also a recommended first-line therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pregabalin: The anticonvulsant pregabalin was more effective than placebo in RCTs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pregabalin was more effective than venlafaxine XR in one RCT” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second-line adjunctive therapies: Adjunctive pregabalin demonstrated good efficacy in a large RCT in patients with GAD who had an inadequate response to prior treatments (Level 2)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICE guideline: pregabalin when SSRIs and SNRIs are not tolerated
BAP guideline: alternative initial treatment, augmentation, and adverse effects
WFSBP guideline: recommended medications and national approval
Network meta-analysis: HAM-A difference from placebo
Meta-analysis of placebo-controlled trials: effect size and dropout
“We included eight randomized-controlled trials (n=2299) in our study, comparing the use of PGB in different dosages and placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In terms of the main outcome, PGB was found to be superior to the placebo group (Hedges' g=0.37; 95% confidence interval 0.30-0.44).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No difference between PGB and placebo groups was observed in terms of the dropout rates.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“PGB was comparable to benzodiazepines in clinical response, but had lower dropout rates than benzodiazepine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Onset, weight gain, and abuse liability
“Pregabalin is reported to be generally well-tolerated in adult patients with GAD and has a rapid onset of action compared to many other pharmacotherapies, approximately one week, as well as comparable efficacy to benzodiazepines” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most significant treatment limiting adverse event appears to be the weight gain associated with pregabalin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, pharmacovigilance data suggest that both pregabalin (and gabapentin) have abuse liability and are associated with overdose fatalities” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Controlled substance schedule, abuse, and dependence: U.S. prescribing information
Buspirone
FDA-approved indication and duration of demonstrated efficacy
Adverse events and discontinuation in premarketing trials
Abuse and dependence potential
CANMAT guideline: second-line agent
“Buspirone was more effective than placebo and as effective as benzodiazepines in several RCTs (Level 1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Limited effectiveness in clinical practice relegates buspirone to a second-line agent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BAP guideline: acute efficacy without relapse-prevention evidence
Cochrane review of azapirones
“Thirty six trials were included in the review, reporting on 5908 participants randomly allocated to azapirones and/or placebo, benzodiazepines, antidepressants, psychotherapy or kava kava. Azapirones, including buspirone, were superior to placebo in treating GAD. The calculated number needed to treat for azapirones using the Clinical Global Impression scale was 4.4 (95% confidence interval (CI) 2.16 to 15.4). Azapirones may be less effective than benzodiazepines and we were unable to conclude if azapirones were superior to antidepressants, kava kava or psychotherapy. Azapirones appeared to be well tolerated. Fewer participants stopped taking benzodiazepines compared to azapirones. The length of studies ranged from four to nine weeks, with one study lasting 14 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Longer term studies are needed to show that azapirones are effective in treating GAD, which is a chronic long‐term illness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Benzodiazepines
FDA-approved indication: alprazolam
Approval status and off-label use of individual benzodiazepines
“As such, alprazolam is the only benzodiazepine to be formally approved by the FDA for the treatment of GAD. However, clonazepam, lorazepam, and diazepam are often used to treat GAD in adults” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Benzodiazepines such as diazepam and clonazepam (both of which are long-acting agents) may be efficacious in treating GAD, although many clinicians choose to limit their use due to concerns about the risks regarding possible misuse and dependence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
FDA boxed warning for the benzodiazepine class, September 2020
Benzodiazepine prescribing, misuse, and overdose data
Boxed warning in the alprazolam prescribing information
NICE guideline: short-term use during crises only
CANMAT guideline: second-line agents for short-term use
“While these agents have level 1 evidence for efficacy, they are recommended as second-line therapy, and usually only for short-term use, because of side effects, dependence, and withdrawal issues.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within these second-line agents, benzodiazepines would be considered first in most cases, except where there is a risk of substance abuse, while bupropion XL would likely be reserved for later.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second-line choices include bupropion XL, buspirone, hydroxyzine, imipramine, quetiapine XR, vortioxetine, as well as the benzodiazepines, alprazolam, bromazepam, diazepam, and lorazepam.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BAP guideline: use after nonresponse to other treatments
AAFP review: onset, dependence, and position in therapy
Meta-analysis: benzodiazepines compared with SSRIs and SNRIs
“A comprehensive literature search yielded 54 articles reporting 56 unique studies with 12,655 participants treated with either pill placebo (6,191 participants), SSRIs (16 trials, 2,712 participants), SNRIs (17 trials, 2,603 participants), or BZs (23 trials, 1,149 participants).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SSRIs (Hedges’ g = 0.33) and SNRIs (Hedges’ g = 0.36) demonstrated significantly lower effect sizes than BZs (Hedges’ g = 0.50).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hydroxyzine
FDA-approved indication
CANMAT guideline: second-line agent
“Hydroxyzine has demonstrated efficacy superior to placebo and similar to benzodiazepines and buspirone in RCTs (Level 1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“however, clinical experience with this agent in the treatment of GAD remains limited.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cochrane review of hydroxyzine
“We included five studies in the review with a total of 884 participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The data from the included studies provide some evidence that hydroxyzine is more effective than placebo for GAD (odds ratio (OR) 0.30, 95% CI 0.15 to 0.58)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In terms of side effects, hydroxyzine was associated with a higher rate of sleepiness/drowsiness than the active comparators (OR 1.74, 95% CI 0.86 to 3.53). There was, however, a high risk of bias in the included studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Even though more effective than placebo, due to the high risk of bias of the included studies, the small number of studies and the overall small sample size, it is not possible to recommend hydroxyzine as a reliable first‐line treatment in GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AAFP review: comparison with benzodiazepines
Second-generation antipsychotics
FDA-approved indications of quetiapine extended release
CANMAT guideline: quetiapine XR as second-line monotherapy
“Quetiapine XR: There is good evidence for the efficacy of quetiapine XR for the management of GAD (Level 1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, quetiapine was associated with more weight gain and sedation, and higher dropout rates due to adverse events compared with placebo or antidepressants” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to tolerability and long-term safety concerns with atypical antipsychotics, this treatment is recommended as a second-line option for patients who cannot be provided antidepressants or benzodiazepines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CANMAT guideline: adjunctive antipsychotics as third-line therapy
“Third-line adjunctive therapies: A meta-analysis of five RCTs of adjunctive atypical antipsychotics found no significant improvement in response rates but higher discontinuation rates versus placebo in patients with refractory GAD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because of the limited evidence for efficacy and their potential for weight gain and metabolic side effects, atypical antipsychotics should be reserved for highly treatment-refractory cases of GAD, and other than quetiapine XR, used only as an adjunctive treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICE guideline: antipsychotics in primary care
BAP guideline: reserved for nonresponse to other interventions
AAFP review: effectiveness and augmentation
Meta-analysis of quetiapine randomized trials
“A total of 2,248 randomized participants in three RCTs were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Unfortunately, the response and the remission rates in only 50 and 150 mg/day of quetiapine-XR (extended-release) were better than those of the placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The rates of pooled overall discontinuation and discontinuation due to adverse events of quetiapine-XR were greater than placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the pooled discontinuation rate due to adverse events of the quetiapine-treated group being significantly higher than that of the placebo-treated group, with RR (95% CI) of 3.18 (2.52, 4.00), I2=0%, it suggests that quetiapine is less tolerable than placebo in the treatment of GAD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the evidence included in this meta-analysis, the significant adverse events consist of somnolence, sexual dysfunction, and extrapyramidal symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis: effect size and tolerability of quetiapine
Fixed-dose trial of quetiapine XR
“Among patients randomized to fixed-dose treatment (quetiapine XR: 50 mg/day, n=234; 150 mg/d, n=241; 300 mg/d, n=241) or placebo (n=235) quetiapine was statistically superior to placebo except at the 300 mg/day dose, wherein side effects were significantly greater” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other antidepressants
CANMAT guideline: agomelatine, imipramine, bupropion XL, vortioxetine, mirtazapine, and trazodone
“Other antidepressants: In two 12-week, double-blind RCTs, agomelatine was found to be more effective than placebo (Level 1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In RCTs, imipramine was superior to placebo and as effective as benzodiazepines for the treatment of GAD (Level 1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, because of side effects and potential toxicity in overdose, imipramine is recommended as a second-line option.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While there are little data on bupropion XL (Level 2), in a 12-week RCT in patients with GAD it was as effective as escitalopram (a first-line option), supporting its use as a second-line option” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Results from two similar, eight-week, placebo-controlled RCTs with vortioxetine were conflicting, with one trial being positive” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a RCT, trazodone was as effective as diazepam (Level 2)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BAP guideline: tricyclic antidepressants, agomelatine, and mirtazapine
Network meta-analysis: mirtazapine and agomelatine
Imipramine and trazodone compared with diazepam
“In this study response rates were 73% for imipramine-treated patients, compared to 69% for patients receiving trazodone and 66% for those receiving diazepam, and 47% for the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While the use of TCAs has largely been supplanted by the use of SSRIs for the treatment of GAD, they still represent a viable option for patients who fail to respond after multiple trials of SSRIs, SNRIs, and adjunctive psychopharmacologic interventions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary
Up to 50% of patients with GAD have an inadequate response to available agents, and 50 to 67% respond adequately to a first treatment trial. Reported response and remission rates are 60% to 68% and 30% to 36% with SSRIs and 56% to 58% and 31% to 38% with SNRIs; another review gives SSRI response in randomized trials as 60% to 75% against 40% to 60% with placebo. One source advises telling patients that treatment periods of up to 12 weeks may be needed to assess efficacy. SSRI and SNRI discontinuation rates are 20% to 23%, associated with nausea, sexual dysfunction, and slow onset. Across 28 anxiety disorder studies (n=5233), relapse prevalence was 36.4% in placebo groups and 16.4% in antidepressant groups; in 6 GAD studies, the odds ratio for relapse after discontinuation was 4.20 (95% CI 2.42 to 7.28). Benzodiazepines carry a class boxed warning for abuse, addiction, physical dependence, and withdrawal; pregabalin is a Schedule V controlled substance; buspirone efficacy beyond 3 to 4 weeks has not been demonstrated in controlled trials. The prescribing information of escitalopram, paroxetine, venlafaxine extended-release, duloxetine, and alprazolam lists GAD among their indications. The indication lists in the prescribing information of pregabalin, a recommended first-line therapy in one source, and of quetiapine extended-release, a second-line choice in the same source, do not include GAD.
Nonresponse to available treatments
“Although numerous agents from various drug classes are available to treat GAD, as many as 50% of patients have inadequate response, constituting an important medical frontier.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Response and remission rates with SSRIs and SNRIs
“However, numerous GAD patients do not achieve remission or response despite adequate dose and duration of SSRIs and SNRIs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Regularly, the rates of response and remission for GAD patients treated with SSRIs are 60%–68% and 30%–36%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, GAD patients treated with SNRIs have demonstrated response and remission rates of 56%–58% and 31%–38%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Delayed onset of antidepressant effect
Adverse effects, adherence, and discontinuation of antidepressants
“Additionally, several GAD patients discontinue the antidepressant therapy. Based on recent evidences, the overall discontinuation rates for SSRIs and SNRIs are 20%–23%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The low acceptability and tolerability of SSRIs and SNRIs are possibly associated with unfavorable side effects of SSRIs and SNRIs including nausea and sexual dysfunction, as well as slow onset of their action.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient concerns about tolerance and dependence
Relapse after antidepressant discontinuation
“The meta-analysis included 28 studies (n=5233) examining relapse with a maximum follow-up of one year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Discontinuation increased the odds of relapse compared with continuing antidepressants (summary odds ratio 3.11, 95% confidence interval 2.48 to 3.89).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Summary relapse prevalences were 36.4% (30.8% to 42.1%; n=28 studies) for the placebo group and 16.4% (12.6% to 20.1%; n=28 studies) for the antidepressant group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Subgroup | Studies | Odds ratio for relapse after discontinuation (95% CI) |
|---|---|---|
| Generalised anxiety disorder (DSM-IV) | “6”View highlighted excerpt for this quote | “4.20 (2.42 to 7.28)”View highlighted excerpt for this quote |
Treatment-resistant anxiety disorder: consensus definition
“The definition of pharmacological treatment resistance in anxiety disorders should rest on at least two failed trials of pharmacological monotherapy with first‐line agents approved for the treatment of anxiety disorders and recommended by guidelines (two different classes, e.g. one SSRI plus one SNRI, clomipramine or pregabalin, in the case of GAD) using at least the minimal approved dose, for the duration of at least 6‐8 weeks each, ideally with documented therapy adherence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who do not respond to multiple courses of therapy are considered to have treatment-refractory illness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This disorder is reportedly frequently under-recognized with less than one-third of patients being adequately treated” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Evidence for combination and augmentation strategies
Place in treatment, anticipated use, and care setting
Summary: anticipated population and place in treatment
Lysergide (DT120 ODT) is investigational; the sponsor anticipates an NDA filing in the first half of 2027, states that its clinical trials are currently the appropriate way to receive the drug, and is evaluating when expanded access may be made available. The sponsor's 2026 corporate presentation counts 4.2 million U.S. adults with GAD or MDD failed by two or more prescription treatments, of 13 million treated with prescription drugs. In the Voyage trial, 78 of 214 participants (36%) had two or more past GAD medications, 65 (30%) had one, and 71 (33%) had none. The sponsor reports that payers expect to manage use with prior authorization in line with other branded psychiatric products. The NICE guideline places complex treatment-refractory GAD at step 4, managed with specialist care such as complex drug or psychological regimens and multi-agency input. One author names, as conditions for adoption, full peer-reviewed reporting of the Voyage and Panorama topline results, formulation bridging, durability and retreatment data, management of functional unblinding, and a scalable model of monitored care.
Summary: care setting, monitoring, and scheduling
The studied paradigm is a single dosing visit with no psychotherapy, continuous monitoring by dosing session monitors, an end of session when checklist criteria are met, and follow-up visits for assessment only. The Phase 3 trials required 8 hours of monitoring; average time to checklist clearance was 5.8 to 6.4 hours across Emerge, Voyage, and Panorama (Part A), and normal activities, including driving, resume the next day. The sponsor proposes 5 to 8 hours of monitoring through the checklist, which it intends to reflect requirements under a potential REMS. It plans delivery through certified third-party treatment sites, citing ~4,000 interventional psychiatry clinics (about half of the estimated Spravato REMS sites), and is engaged with the VA. Lysergide is a Schedule I substance: after FDA approval, the DEA and states must reschedule the product before it can be marketed, state scheduling may delay sale, and the active ingredient would remain subject to manufacturing quotas.
Target population named by the company: adults failed by two or more treatments
| Population | Quoted count | Quoted description |
|---|---|---|
| U.S. adults with GAD or MDD | “50 million” | “US Adults with GAD / MDD” |
| Diagnosed | “26 million” | “Diagnosed with GAD / MDD” |
| Treated with prescription drugs | “13 million” | “Rx Treated” |
| Failed by two or more prescription treatments | “4.2 million” | “Failed by 2+ Rx” |
Guideline step for treatment-refractory GAD: NICE stepped care
Treatment paradigm: single administration without psychotherapy
Session length and real-world delivery model
Monitoring duration proposed for commercial use
Care setting: interventional psychiatry clinics
| Item | Quoted value |
|---|---|
| Slide title | “Modest Adoption Yields Significant Opportunity Given Large and Growing Delivery Ecosystem” |
| Interventional psychiatry clinics | “~4,000” |
| Basis for the clinic count | “Represents approximately half of estimated number of sites in the Spravato® REMS program.” |
| Price assumption | “Assumes midpoint of surrogate pricing range for Spravato®. The price of DT120 ODT has not been established.” |
Supervised treatment model and referral pathways: third quarter 2026 earnings call
Department of Veterans Affairs as a care setting
Monotherapy as the studied use and combination use as anticipated practice
Payer expectations reported by the company
Session monitoring expected by FDA in clinical investigations of psychedelic drugs
Supervised-administration analog: esketamine REMS
Procedure codes for monitoring during psychedelic medication therapy
Conditions for adoption named in a drug review
“The phase 2b dose-finding study provides a credible signal of rapid and durable anxiolytic activity after one 100 microgram administration without protocol-mandated psychotherapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adoption will depend on full peer-reviewed reporting of the positive Voyage and Panorama phase 3 topline results, formulation bridging, durability and retreatment data, management of functional unblinding, and a scalable monitored-care model.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Heterogeneity of treatment effect
Baseline severity and antidepressant efficacy in GAD: individual participant data
“For GAD and PD, severity moderated antidepressant efficacy. The antidepressant–placebo difference was 1.4 (95% CI: 0.4–2.5; SMD: 0.21) Hamilton Anxiety Rating Scale (HAM‐A) points for participants with mild GAD (baseline HAM‐A = 10), increasing to 4.0 (3.4–4.6; SMD: 0.45) or greater for severely ill participants (HAM‐A ≥ 30).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Half of the GAD trials specified a minimum HAM‐A score of 20, for instance, even though most primary care patients with GAD have scores below 20 (Rollman et al., 2005).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age as a moderator of psychotherapy and medication effects
“Mean age of the sample was a significant moderator of psychotherapy outcomes. A lower mean age predicted a larger treatment effect size in psychotherapy (β = −0.013, p < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean age was not associated with outcome in medication studies (p > 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was no significant relationship between effect size and treatment dose (number of sessions or medication dosage), treatment quality, year of publication, fixed versus flexible dose, percent comorbidity, percent female, or pretreatment severity (all p > 0.10).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Older adults
“Twenty-seven trials (14 pharmacological, 13 psychotherapeutic) fulfilled the inclusion criteria, reporting results from 2373 baseline participants.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Pooled treatment effects for pharmacological (OR=0.32, 95% CI: 0.18, 0.54) and psychotherapeutic (OR=0.33, 95% CI: 0.17, 0.66) trials were similar, with findings in each case favoring active interventions over control conditions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
DT120 in Voyage: change in HAM-A score at Week 12 by subgroup
| Subgroup | Placebo-adjusted LS mean change (SE) |
|---|---|
| All participants | “−5.4 (1.0)” |
| Time since GAD symptoms began, less than 22 years (n = 107) | “−5.9 (1.4)” |
| Time since GAD symptoms began, 22 years or more (n = 107) | “−4.7 (1.5)” |
| Previous GAD medications, fewer than 2 (n = 136) | “−4.2 (1.2)” |
| Previous GAD medications, 2 or more (n = 78) | “−5.6 (1.7)” |
| Male (n = 77) | “−7.1 (1.7)” |
| Female (n = 137) | “−5.5 (1.2)” |
DT120 in Panorama: subgroups and stability of subgroup estimates
Functional unblinding and dose in the phase 2b trial
“All doses of MM120 produced transient perceptual, cognitive, and emotional effects leading to participant unblinding.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Central rater blinding was preserved in more than 80% of HAM-A assessments,31 despite approximately 85% of participants correctly identifying assignment to active treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Expectancy and blinding in psychedelic trials
“While psychedelic RCTs have generally shown promising results, with large effect sizes reported, we argue that treatment effect sizes in psychedelic RCTs are likely over-estimated due to de-blinding of participants and high levels of response expectancy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest that psychedelic RCTs should routinely measure de-blinding and expectancy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prior psychedelic exposure: FDA recommendation
Prior psychedelic exposure in the DT120 phase 3 trials
Functional unblinding in a health technology assessment of another psychedelic treatment
Company statement on heterogeneous populations
Care management intervention strategies
Stepped care for GAD: NICE
Monitoring of drug treatment: NICE
Collaborative care in primary care: the CALM trial
“Between June 2006 and April 2008, 1004 primary care patients with PD, GAD, SAD, and/or PTSD were enrolled in the CALM study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CALM allowed choice of cognitive behavioral therapy (CBT), medication, or both; included real-time web-based outcomes monitoring to optimize treatment decisions and a computer-assisted program to optimize delivery of CBT by non-expert care managers who also assisted primary care providers in promoting adherence and optimizing medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 12 months, response and remission rates (CALM vs. UC) were 63.66% (58.95–68.37) vs. 44.68% (39.76–49.59), and 51.49% (46.60–56.38) vs. 33.28% (28.62–37.93), with a number needed to treat (NNT) of 5.27 (4.18–7.13) for response and 5.5 (4.32–7.55) for remission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Collaborative care for anxiety: Cochrane review
“The results also demonstrated significantly greater improvement in anxiety outcomes for adults with anxiety treated with the collaborative care model in the short‐term (SMD ‐0.30, 95% CI ‐0.44 to ‐0.17; RR 1.50, 95% CI 1.21 to 1.87), medium‐term (SMD ‐0.33, 95% CI ‐0.47 to ‐0.19; RR 1.41, 95% CI 1.18 to 1.69), and long‐term (SMD ‐0.20, 95% CI ‐0.34 to ‐0.06; RR 1.26, 95% CI 1.11 to 1.42).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Collaborative care is associated with significant improvement in depression and anxiety outcomes compared with usual care, and represents a useful addition to clinical pathways for adult patients with depression and anxiety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Symptom-triggered retreatment after a single dose in the DT120 phase 3 trials
Patient, provider, and site support planned by the company
“Referral & Treatment Coordination” (opens the source at this quote in a new tab)
“Treatment-Day Logistics” (opens the source at this quote in a new tab)
“INTEGRATED COMMERCIAL SUPPORT MODEL” (opens the source at this quote in a new tab)
“Connecting patients, providers and sites of care” (opens the source at this quote in a new tab)
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Summary: symptom change, response, and remission
In the phase 3 trials, which compared a single dose of DT120 ODT 100 µg with placebo and have reported company topline results, the LS mean HAM-A total score decreased by 11.6 points (Voyage) and 9.8 points (Panorama) at Week 12, compared with 6.2 and 4.7 points with placebo. The placebo-adjusted differences of 5.4 and 5.1 points compare with a minimal clinically important difference of 2.5 points used in the phase 2b trial. At Week 12, 43% (Voyage) and 32% (Panorama) of participants given DT120 had a response (HAM-A improvement of 50% or more) and 14% and 15% a remission (HAM-A of 7 or less), compared with 16% and 14% (response) and 4% and 4% (remission) with placebo. In the phase 2b trial, which used capsules, response at Week 12 occurred in 26 of 40 participants (65.0%) given 100 µg and 12 of 39 (30.8%) given placebo, and remission in 19 (47.5%) and 8 (20.5%).
Summary: onset, durability, and the dosing session
Differences from placebo were present early: CGI-S change at Day 2 differed by -0.8 in both phase 3 trials, and HAM-A change at Week 1 by -7.7 (Voyage) and -5.3 (Panorama) points. The controlled comparison covers 12 weeks after one dose. In the 40-week extensions participants could receive open-label DT120 ODT (in Voyage, up to four additional doses based on symptom severity); in interim analyses of partial data (cutoffs July 15, 2026 and August 11, 2026), 60% of 37 Voyage participants and 48% of 27 Panorama participants given DT120 in Part A had a HAM-A response at Week 28. FDA guidance asks sponsors to follow participants beyond Week 12 for symptom recurrence or a need for repeat dosing. Transient perceptual, affective, and emotional effects occurred primarily on the dosing day. Participants were observed by dosing session monitors for at least 8 hours and until they cleared an end-of-session checklist; mean time to clearance was 6.4 hours in Voyage and 6.2 hours in Panorama, and by hour 8, 92% (topline announcement) or 90% (poster) of Voyage participants, 94% of Panorama participants, and 97% across more than 1,000 phase 3 sessions through September 10, 2026 had cleared it. The sponsor states that normal activities, including driving, resume the next day.
Definitions of response and remission in anxiety disorders
“Response is generally regarded as a clinically meaningful improvement in symptoms, while remission, the goal of treatment, is generally thought of as the absence or near absence of symptoms following illness, accompanied by a return to premorbid levels of functioning.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“While no universally accepted criteria exist, a commonly used threshold for response is a >50% improvement in the total score, while for remission, various cutoff points have been used.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HAM-A severity bands and minimal clinically important difference
“score range, 0-56; higher scores indicate greater severity; ≤7 indicates no or minimal anxiety; 8-14, mild; 15-23, moderate; and ≥24, severe” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The minimal clinically important difference was 2.5 points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Expected HAM-A differences from placebo with existing drugs: network meta-analysis
“This analysis is based on 89 trials, which included 25 441 patients randomly assigned to 22 different active drugs or placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Duloxetine (MD -3·13, 95% credible interval [CrI] -4·13 to -2·13), pregabalin (MD -2·79, 95% CrI -3·69 to -1·91), venlafaxine (MD -2·69, 95% CrI -3·50 to -1·89), and escitalopram (MD -2·45, 95% CrI -3·27 to -1·63) were more efficacious than placebo with relatively good acceptability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Quetiapine (MD -3·60 95% CrI -4·83 to -2·39) had the largest effect on HAM-A but it was poorly tolerated (odds ratio 1·44, 95% CrI 1·16-1·80) when compared with placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pooled effect sizes of psychotherapy and medication
“Psychotherapy showed a medium to large effect size (g = 0.76) and medication showed a small effect size (g = 0.38) on GAD outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because medication studies had more placebo control conditions than inactive conditions compared to psychotherapy studies, effect sizes between the domains should not be compared directly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
DT120 in Voyage: response and remission at Week 12
| Outcome at Week 12 | DT120 ODT | Placebo ODT | Placebo-adjusted difference |
|---|---|---|---|
| HAM-A response rate (≥50%) | “43%” | “16%” | “27% (p<0.0001)” |
| HAM-A remission rate (≤7) | “14%” | “4%” | “10% (p=0.0222)” |
DT120 in Panorama: response and remission at Week 12
| Outcome at Week 12 | DT120 ODT 100 µg | Placebo ODT | Placebo-adjusted difference |
|---|---|---|---|
| HAM-A response rate (≥50%) | “32%” | “14%” | “18% (p<0.05)” |
| HAM-A remission rate (≤7) | “15%” | “4%” | “12% (p<0.05)” |